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Abstract
Pediatric low-grade gliomas (PLGGs) are a heterogeneous group of tumors that collectively represent the
most common childhood brain cancer. Despite favorable outcomes with surgical and adjuvant therapies,
majority of patients suffer from long-term treatment-related morbidities and recurrent/inoperable disease.
This necessitates a deeper understanding of PLGG biology to aid development of molecular diagnostics
and low-toxicity targeted therapeutics.
Hitherto, PLGGs have been defined by activating mutations that dysregulate the MAPK signaling pathway,
leading to clinical testing of RAF/MAPK inhibitors for PLGGs. Interestingly, recent large-scale sequencing
efforts discovered novel gene fusions in PLGGs and we identified the unique recurrent association of
tumor suppressor Quaking (QKI) with distinct proto-oncogenes, MYB and RAF1, in different PLGG subtypes. We hypothesized that MYB-QKI and QKI-RAF1 function via novel oncogenic mechanisms invoking a
two-hit mechanism of gain-of-function in the MYB/RAF1 oncoproteins collaborating with QKI loss of
putative tumor suppressor function, describing for the first time a unique gene fusion setting involving
both fusion partners with implications for therapeutic targeting.
Utilizing heterologous cell model systems and in vivo mouse models, we found MYB-QKI and QKI-RAF1
are capable of driving oncogenesis. Furthermore, MYB-QKI is a specific driver mutation defining
angiocentric gliomas and mediates tumorigenesis via a tri-partite mechanism: (1)MYB oncogenic
activation via truncation, (2)rearrangement led enhancer translocation that drives MYB-QKI expression
and (3)LOH of QKI tumor suppressor. In contrast, QKI-RAF1 drives some pilocytic astrocytomas via
aberrant activation of the MAPK pathway in a QKI-dimerization dependent manner. We also found
differential response to RAF targeted therapy in QKI-RAF1, compared to BRAF fusions in PLGGs, due to
QKI-mediated dimerization. Hence, our study highlights distinct roles for the same gene, QKI in supporting
the oncogenic functions of MYB and RAF1 in different PLGG-gene fusions.
Overall, our study has uncovered distinct molecular mechanisms associated with different QKI gene
fusions in PLGGs. We show that MYB-QKI is specific to angiocentric gliomas and mediates a unique
oncogenic program, and with QKI-RAF1 we demonstrate how mutational context guides differential
response to targeted therapy. Therefore, our study has important clinical implications on molecular
diagnostics and targeted therapy for these rather understudied class of childhood brain tumors.
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ABSTRACT
MOLECULAR MECHANISMS OF ONCOGENESIS & PRECISION MEDICINE
APPROACHES FOR PEDIATRIC LOW-GRADE GLIOMAS
Payal Jain
Adam C. Resnick, PhD

Pediatric low-grade gliomas (PLGGs) are a heterogeneous group of tumors that collectively
represent the most common childhood brain cancer. Despite favorable outcomes with surgical
and adjuvant therapies, majority of patients suffer from long-term treatment-related morbidities
and recurrent/inoperable disease. This necessitates a deeper understanding of PLGG biology to
aid development of molecular diagnostics and low-toxicity targeted therapeutics.

Hitherto, PLGGs have been defined by activating mutations that dysregulate the MAPK signaling
pathway, leading to clinical testing of RAF/MAPK inhibitors for PLGGs. Interestingly, recent
large-scale sequencing efforts discovered novel gene fusions in PLGGs and we identified the
unique recurrent association of tumor suppressor Quaking (QKI) with distinct proto-oncogenes,
MYB and RAF1, in different PLGG sub-types. We hypothesized that MYB-QKI and QKI-RAF1
function via novel oncogenic mechanisms invoking a two-hit mechanism of gain-of-function in the
MYB/RAF1 oncoproteins collaborating with QKI loss of putative tumor suppressor function,
describing for the first time a unique gene fusion setting involving both fusion partners with
implications for therapeutic targeting.

Utilizing heterologous cell model systems and in vivo mouse models, we found MYB-QKI and
QKI-RAF1 are capable of driving oncogenesis. Furthermore, MYB-QKI is a specific driver
vii

mutation defining angiocentric gliomas and mediates tumorigenesis via a tri-partite mechanism:
(1)MYB oncogenic activation via truncation, (2)rearrangement led enhancer translocation that
drives MYB-QKI expression and (3)LOH of QKI tumor suppressor. In contrast, QKI-RAF1
drives some pilocytic astrocytomas via aberrant activation of the MAPK pathway in a QKIdimerization dependent manner. We also found differential response to RAF targeted therapy in
QKI-RAF1, compared to BRAF fusions in PLGGs, due to QKI-mediated dimerization. Hence, our
study highlights distinct roles for the same gene, QKI in supporting the oncogenic functions of
MYB and RAF1 in different PLGG-gene fusions.
Overall, our study has uncovered distinct molecular mechanisms associated with different QKI
gene fusions in PLGGs. We show that MYB-QKI is specific to angiocentric gliomas and mediates
a unique oncogenic program, and with QKI-RAF1 we demonstrate how mutational context guides
differential response to targeted therapy. Therefore, our study has important clinical implications
on molecular diagnostics and targeted therapy for these rather understudied class of childhood
brain tumors.
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CHAPTER 1: Introduction
Pediatric Brain Cancer
Childhood brain cancer is defined as a disease where abnormal cells accumulate in the tissues of
the brain and spinal cord, which together make up the central nervous system (CNS). CNS tumors
represent the most common cancer in children 0-14 years with infants (<1 year old) showing the
highest brain tumor incidence of all children, even surpassing leukemia (Ostrom, de Blank, et al.,
2015; Ostrom, Gittleman, et al., 2015) (Fig. 1.1). Furthermore, the overall incidence of brain and
CNS tumors in children has increased between the years of 2000 and 2010 (Gittleman et al.,
2015), and it is estimated that 4,630 cases will be diagnosed in 2016 (Ostrom, Gittleman, et al.,
2015).
Despite advances in sequencing technologies and the advent of molecular/cellular-targeted
therapies in oncology, there is a significant lag in the field of pediatric brain tumors where novel
targeted therapies are yet to be adopted in the clinic. As a consequence, pediatric brain tumors
have surpassed leukemias as the leading cause of cancer-related death in children (Patel et al.,
2014; Smith, Altekruse, Adamson, Reaman, & Seibel, 2014). Even comparison with adult brain
tumors, which are distinct histological and molecular entities from their pediatric counterparts,
shows that pediatric brain and CNS tumors have a higher incidence and mortality rate than adult
brain tumors (Fig. 1.2). This necessitates a deeper molecular understanding of pediatric brain
tumors that can guide development of novel biomarkers and targeted therapies.
Pediatric brain tumors represent a diverse group of diseases that are classified by the World
Health Organization (WHO) into large groups based on predominant cell type, location of tumors
and level of malignancy. Based on the WHO classification, pediatric brain tumors mainly
1

comprise of glial tumors/gliomas (astrocytomas, oligodendrogliomas, oligoastrocytomas,
ependymomas),

germ

cell

tumors

(GCTs),

embryonal

tumors

of

neuronal

origin

(medulloblastoma, atypical teratoid rhabdoid tumors [ATRTs], CNS primitive neuroectodermal
tumors [PNETs] and epithelial tumors with multiple rosettes [EMTRs]), and other rare tumors
such as craniopharyngiomas and tumors of mixed neuronal-glial lineages (Louis et al., 2007)
(Fig. 1.3). Each tumor type has been found to have preference for site of occurrence, with
majority occurring below a structure called the tentorium cerebeli that divides the forebrain from
posterior fossa and hindbrain structures. Pediatric tumors are mostly found in infratentorial
regions such as cerebellum, the optic pathway and the brainstem (Pollack, 1999). Recent largescale sequencing studies are helping to add annotation based on mutational context to these
diverse tumor types, beginning an era of molecular sub-classification, mutation-based diagnosis
and identification of novel targets.
Gliomas are the most common primary tumors found in children (52.9%) and are further subdivided on the basis of aggressiveness, grade I (benign) to grade IV (most malignant and
aggressive). Further sub-grouping has resulted in two broad clinical and commonly known
categories: low-grade gliomas (LGG, grades I and II) and high-grade gliomas (HGG, grades III
and IV). Amongst these diverse tumor sub-types, we studied the molecular mechanisms driving
pediatric low-grade gliomas (PLGGs) that are often considered ‘low-risk’ tumors but can lead to
devastating long-term consequences in children.

Pediatric Low-Grade Gliomas
PLGGs are the most commonly diagnosed brain tumor in children and represent a heterogeneous
group of histological entities, ranging from grade I pilocytic astrocytomas (PAs) to grade II
diffuse astrocytomas (DAs), angiocentric gliomas (AGs), pleomorphic xanthoastrocytomas
2

(PXAs), and gangliogliomas (Louis et al., 2007). These tumors account for 30-50% of the CNS
tumors in children and are characterized by their slow growth and less aggressive behavior
(Qaddoumi, Sultan, & Gajjar, 2009). Most PLGG patients have favorable outcomes with surgical
resection but therapeutic challenges remain in cases with incompletely resected tumors in
inaccessible brain regions such as the hypothalamus/optic pathway, brain stem and basal ganglia.
Overall, up to 20% of patients suffer from recurrent, progressive or inoperable disease (Sievert &
Fisher, 2009).
Adjuvant radiation and chemotherapy improve progression-free survival, however, these
regimens are associated with significant long-term morbidities in nearly 65% cases due to toxic
side effects on the developing CNS (Merchant, Conklin, Wu, Lustig, & Xiong, 2009; Sievert &
Fisher, 2009; Stokland et al., 2010; Taphoorn et al., 1994). Current chemotherapy regimens used
in the clinic include carboplatin. vincistrine, vinblastine, cisplatin with etoposide, and
temozolomide (Ater et al., 2012; Bouffet et al., 2012; Massimino et al., 2010). Survivors often
suffer from late effects of both disease and treatment such as severe cognitive and neurological
defects, risk of secondary cancers, neuro-endocrine disorders, infertility and other issues in
adulthood. Hence, despite a 20-year overall survival of 87% in PLGG patients with current
treatment options (P. Bandopadhayay et al., 2014), there is a large unmet need for combined
molecular-histopathological diagnosis of these diverse tumors, and improved treatment plans that
can target patient-specific mutations leading to better quality of life for survivors.

Landscape of genomic alterations in PLGGs
More than a decade ago, the first insight into the molecular/genetic alterations of PLGGs came
from tumors arising due to genetic predisposition syndromes such as neurofibromatosis 1 (NF1)
associated pilocytic astrocytomas (Gutmann, Donahoe, Brown, James, & Perry, 2000; Kluwe et
3

al., 2001; Lau et al., 2000) and tuberous sclerosis complex (TSC) related LGGs (called
Subependymal Giant Cell Astrocytoma or SEGA) (Shepherd, Scheithauer, Gomez, Altermatt, &
Katzmann, 1991). These findings highlighted aberration of canonical signaling pathways driven
by somatic mutations in NF1 or TSC-associated PLGGs. Subsequently, a plethora of studies
utilizing cytogenetics, single nucleotide polymorphism (SNP) arrays, Sanger sequencing, nextgeneration sequencing (whole-genome, exome and RNA sequencing) and epigenetic mapping
have helped define the molecular/genetic underpinnings of diverse PLGGs that are not associated
with genetic predisposition syndromes. These large-scale studies have discovered various
mutations, gene rearrangements forming gene fusions, and copy number alterations that are
distinct to specific tumor sub-types.
As shown in figure 1.4, we have categorized PLGG-associated mutations and gene fusions that
have been discovered in the past few years by our group and others (D. T. Jones et al., 2009; D.
T. W. Jones et al., 2013). Such categorization has shown promise in associating the unique
molecular profiles with clinical progression and therapeutic response in some PLGG sub-types
(mostly grade I PAs) but further research is required to delineate molecular mechanisms and
response to therapy for grade II tumors. Furthermore, very few studies have explored the
therapeutic response of distinct mutations within the same PLGG sub-type (Fig. 1.4) and current
clinical trials fail to address such detailed molecular classification that could critically determine
success/failure of PLGG targeted therapies.

BRAF mutations and gene fusions
Large-scale profiling studies over the past few years have found grade I PAs to have relatively
stable genomes with limited genetic alterations that often lead to aberrant activation of the
mitogen associated protein kinase (MAPK) pathway. NF1 associated PLGGs have biallelic
4

inactivation of the NF1 gene resulting in loss of neurofibromin protein. NF1 is known to act as a
tumor suppressor by inhibiting RAS in the pathway, thereby resulting in aberrant MAPK
activation in NF1 affected PAs (Gutmann et al., 2000; Kluwe et al., 2001; Lau et al., 2000) (Fig
1.5). In contrast to NF1 associated tumors that account for 15-20% of PAs, sporadic PAs were
found to harbor somatic gene rearrangements involving the kinase domain of BRAF gene with a
gene called KIAA1549, also activating the MAPK pathway (D. T. Jones et al., 2008; Pfister et al.,
2008). BRAF is an upstream kinase involved in the MAPK signaling pathway (Fig 1.5) and the
KIAA1549-BRAF fusion arises due to tandem duplication at 7q34 followed by fusion of 5’
KIAA1549 and 3’ BRAF. The fusion transcript can also activate the PI3K/AKT/mTOR pathway
via crosstalk between the MAPK and PI3K/mTOR pathways (Kaul, Chen, Emnett, Dahiya, &
Gutmann, 2012). Almost 65% of sporadic PAs harbor the KIAA1549-BRAF fusion but nearly all
PAs display constitutive activation of the MAPK pathway via other mutations in the MAPK
signaling axis (Jacob et al., 2009; D. T. Jones et al., 2008; Sievert et al., 2009) as described
below. Interestingly, better clinical outcomes are correlated with the occurrence of KIAA1549BRAF in cerebellar PAs (Hawkins et al., 2011).
Next generation sequencing studies have discovered alternative BRAF-activating mutations that
occur at a lower frequency compared to KIAA1549-BRAF in cerebellar PAs, such as novel BRAF
gene fusions (FAM131-BRAF, FXFR1-BRAF, MACF1-BRAF, RNF130-BRAF, MKRN130-BRAF,
GNAI1-BRAF), CRAF/RAF1 gene fusions (QKI-RAF1, SRGAP3-RAF1, FYCO-RAF1) and
BRAFV600E mutations (Bacon, Endris, & Rappold, 2009; D. T. Jones et al., 2009; D. T. W.
Jones et al., 2013; J. Zhang et al., 2013) (Fig 1.6). These studies indicate that grade I PAs are
primarily a single pathway disease where a single hit in the MAPK pathway is sufficient to
induce neoplasia. Interestingly, studies have shown also that BRAF/other mutation driven MAPK
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pathway activation can lead to oncogene induced senescence in LGGs (Jacob et al., 2011). This
partly accounts for their indolent growth pattern and absence of malignant progression to HGGs.

Non-BRAF mutations and gene fusions
In contrast to the predominance of BRAF alterations in cerebellar PAs, non-cerebellar PAs are
more commonly associated with FGFR1 and PTPN11 mutations, FGFR1-TACC1 fusions, and
novel NTRK2 gene fusions (QKI-NTRK2 and NACC2-NTRK2) (Fig 1.6). These tumors occur in
less surgically accessible brain regions and pose a major therapeutic challenge. Since FGFR and
NTRK are upstream receptors of the MAPK and PI3K/mTOR pathways, mutations and gene
fusions can constitutively activate both signaling cascades (D. T. W. Jones et al., 2013).
Further histopathological annotations have classified another WHO grade I tumor called
angiocentric glioma (AG) (Buccoliero et al., 2013). These epilepsy-associated, cerebral tumors
are mostly found in children and young adults and alterations in the MYB gene (truncation of 3’
end and MYB-QKI gene fusion) have been found in a few cases of AGs (Ramkissoon et al., 2013;
J. Zhang et al., 2013). However there is no further information about the mechanism of action and
specific correlation of MYB alterations with occurrence of AGs. We have addressed these
questions revolving around MYB-QKI and our findings are described in chapter 3.
Grade

II

pediatric

gliomas

encompass

diffuse

astrocytomas

(DAs),

pleomorphic

xanthoastrocytomas (PXAs) and ganglioglomas. While these tumors are rare in the pediatric
population, they can lead to significant morbidity in patients due to occurrence at unresectable
sites in the brain and having diffuse/infiltrative morphology, leading to incomplete surgical
resection. Furthermore, DAs are found to harbor distinct genetic alterations as compared to
MAPK altered PAs. These include chromosomal duplication at 8q13.1 leading to truncation of
negative regulatory domain of the transcription factor MYBL1 (Ramkissoon et al., 2013).
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Approximately 25% of cerebral gliomas with a diffuse morphology harbor alterations in MYB or
MYBL1 whereas another 25% show FGFR1 duplication (J. Zhang et al., 2013) (Fig 1.6). FGFR1
mutated grade II tumors also depict MAPK and PI3K/mTOR alterations. Overall, MYB and
FGFR mutations are useful biomarkers and effective therapeutic targets for these clinically
challenging tumors.
QKI gene fusions: MYB-QKI, QKI-RAF1 and QKI-NTRK2
In our analysis of whole genome sequencing (WGS), RNA sequencing or exome sequencing data,
we also found the MAPK pathway to be ubiquitously affected in most PLGGs. Interestingly, we
found non-BRAF gene fusions mediating changes in these well-known signaling pathways and
activating other unique oncogenic mechanisms in PLGGs. In particular, we and others have
identified the recurrence of the gene fusions MYB-QKI, QKI-RAF1 and QKI-NTRK2 that share
the Quaking (QKI) fusion partner, an RNA binding protein and putative tumor suppressor, fused
to known proto-oncogenes (D. T. W. Jones et al., 2013; J. Zhang et al., 2013) (Fig 1.7). We refer
to this new class of gene fusions as Quaking (QKI) fusions and the recurrence of QKI as a fusion
partner strongly indicates a role for QKI gene fusion mediated oncogenic processes in driving
PLGGs. This provides a unique platform for identifying the mechanisms by which QKI
collaborates with distinct fusion partners to drive PLGG pathogenesis, thereby suggesting an
emergent theme for their contribution to low-grade glioma biology. My thesis will discuss the
oncogenic mechanism of action and therapeutic targeting of the MYB-QKI and QKI-RAF1
fusions.
QKI belongs to a family of RNA binding proteins known as the signal transduction and
activation of RNA (STAR) proteins. These proteins share a single, highly conserved, maxi Khomology (KH)–RNA binding domain (RBD). Flanking the KH domain is the N-terminus
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QUAKING1 (QUA1) domain, required for homodimerization (HD), and the C-terminus
QUAKING2 (QUA2) domain, necessary for RNA recognition and binding (Vernet & Artzt,
1997) (Fig 1.7). QKI isoforms (QKI 5/6/7) act at various levels of post-transcriptional gene
regulation, including mRNA export, RNA stability, pre-mRNA splicing and protein translation,
in several cell-specific contexts. The most well studied role of QKI has been its regulation of glial
development and myelination in the CNS (Vernet & Artzt, 1997). Interestingly, alterations in
QKI expression are found in ~ 30% of HGGs (A. J. Chen et al., 2012) where QKI acts as a
putative tumor suppressor gene. Furthermore, recent large-scale genomic analyses have revealed
QKI as a critical cancer gene lost in several cancer types (Lawrence et al., 2014). However,
structural alterations of QKI seen in the MYB-QKI, QKI-RAF1 and QKI-NTRK2 gene fusions
have not been previously described. My structural analysis of QKI-RAF1 and QKI-NTRK2
reveals that rearrangement of chromosome 6q results in a loss of QKI’s C-terminal Y-rich region
in addition to loss of the QUA2 domain in QKI-RAF, whereas MYB-QKI loses QKI N-terminal
regions, including RBD and HD domains (Fig 1.7). However, QKI retains the QUA1 region in
QKI-NTRK2 and QKI-RAF1 fusion proteins that has homo-dimerization properties.
MYB was first discovered as the cellular homolog (c-myb) of highly oncogenic v-myb found in
the chicken leukemia viruses AMV and E26 (Gonda & Bishop, 1983; Klempnauer, Gonda, &
Bishop, 1982). This association between altered MYB and avian leukemias suggested a potential
role for MYB as a proto-oncogene in human cancer. During normal development, MYB functions
as a transcription factor that regulates proliferation and differentiation in specific cell lineages. In
hematopoiesis, MYB plays a critical role in maintaining the undifferentiated state of
hematopoietic stem cells (Sicurella et al., 2001). However, MYB expression declines postnatally
in most differentiated tissues including the CNS, with some expression persisting in the
neurogenic foci in adult brain (Malaterre et al., 2008). This implicates that MYB plays a role in
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stimulating proliferation and suppressing differentiation. These functions are consistent with
MYB’s established role as a proto-oncogene in tumors. However, the mechanism of MYB
dysregulation differs in different cancer types. In human leukemias and several epithelial cancers,
MYB is often deregulated via chromosomal translocations, activating truncations, and/or
amplifications (Pelicci, Lanfrancone, Brathwaite, Wolman, & Dalla-Favera, 1984; Zhou & Ness,
2011). Provided that the N-terminus of MYB contains the DNA binding domain (DBD) and the
C-terminus contains a negative regulatory domain (NRD) (Fig 1.7), which interacts with the
DBD to auto-inhibit its function, alterations in the N or C terminus both enhance the
transformative capacity of MYB. This has been evidenced by the up-regulation of MYB activity
in cancers with C-terminally truncated MYB (Dash, Orrico, & Ness, 1996; Zhou & Ness, 2011).
In addition, loss of the 3’UTR of MYB, that harbors negative regulatory microRNA binding sites,
has also been found in several cancers (Fehr et al., 2011; M. Persson et al., 2009). Interestingly,
the MYB-QKI fusion leads to loss of MYB NRD (Fig 1.7) that could lead to constitutive
activation of MYB in MYB-QKI. This observation, along with loss of QKI RBD, forms the basis
of my hypothesis for Aim 1 of my thesis (chapter 2), as described below.
AIM 1: Investigate the oncogenic mechanism of action of MYB-QKI in PLGGs with a focus on
independent and collaborative roles of MYB and QKI in mediating gliomagenesis. This aim will
test the hypothesis that there is a gain-of-function of the MYB proto-oncogene via loss of its
regulatory elements along with loss of tumor suppressor functions of QKI in a specific subset
of PLGGs called angiocentric gliomas.
RAF-1 (or CRAF) is a serine-threonine kinase involved in the MAPK signaling cascade and is
one of the three existing RAF isoforms (A-RAF, B-RAF, C-RAF). All three RAF proteins share
similar protein domains, common mechanisms of activation and downstream effectors. Activation
of up-stream RAS by tyrosine kinase auto-phosphorylation recruits RAF to the membrane where
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RAF is activated and in turn activates the MAPK/ERK pathway by phosphorylating the
MAPK/ERK kinase (MEK) (Emerson et al., 1995; Moodie, Willumsen, Weber, & Wolfman,
1993; Nassar et al., 1995). The N-terminal domains of RAF1 physically inhibit the kinase activity
of RAF1 (Cutler, Stephens, Saracino, & Morrison, 1998) and membrane recruitment by RAS
relieves this negative regulation of RAF kinase activity (Fig. 1.5). The structural gene
rearrangement in QKI-RAF1 leads to loss of N-terminal auto-inhibitory domains, thereby
suggesting constitutive kinase activity. This observation, along with loss of portion of QKI RBD,
forms the basis of my hypothesis for Aim 2 (chapter 3), of my thesis, as described below.
AIM 2: Investigate the oncogenic mechanism of action of QKI-RAF1 in PLGGs with a focus on
independent and collaborative roles of QKI and RAF1 in mediating gliomagenesis. This aim will
test the hypothesis that dimerization domains in truncated QKI contribute to constitutive
homo/hetero-dimerization of QKI-RAF1, thereby causing activation of downstream MAPK and
PI3K pathway and oncogenic transformation.
These aims would explore an unaddressed avenue in the field of oncogenic gene fusions where
usually one fusion partner is found to drive transformation. Our study will expose unique
collaborative mechanisms between fusion partners that lead to pediatric brain tumors and could
also provide mechanistic insight into the oncogenic mechanism mediated by gene fusions in adult
cancers.

Targeted therapy for PLGGs: Need for molecular-based diagnosis and
patient stratification for personalized medicine
Due to the tight association of specific mutations/gene fusions with PLGG tumor subtypes,
PLGGs are an excellent candidate for molecular diagnosis and targeted therapy. Some efforts
towards this end and future possibilities are described below.
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MAPK/PI3K/mTOR targeted inhibitors
Due to extensive involvement of the RAF proteins and subsequent MAPK/PI3K pathway
activation in multiple cancers, several RAF and MAPK-targeted small molecule inhibitors have
been developed in the past few years. Pharmacological intervention with RAF (vemurafenib and
dabrafenib) and MEK (trametinib) inhibitors has significantly improved median survival of
melanoma patients with BRAF alterations (Long et al., 2011). Despite its success against the
constitutively active BRAF V600E mutation found in melanomas, when tested in PLGGs
containing BRAF fusions (KIAA1549-BRAF) or MAPK pathway activation mutations other than
BRAFV600E, vemurafenib induced paradoxical activation (A. J. Sievert et al., 2013). This is due
to stabilization of RAS-dependent RAF dimerization by RAF inhibitors (vemurafenib or its
research analog PLX4720) in cells expressing wild-type RAF proteins (Cutler et al., 1998;
Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2011). Even a phase II study
with sorafenib (multi-kinase inhibitor towards BRAF) for MAPK-altered PLGGs showed
significant early tumor progression due to paradoxical activation of the MAPK pathway
(Karajannis et al., 2014). These findings highlight the therapeutic nuances of targeting PLGGs
and how important it is to understand the distinct molecular mechanisms driving distinct tumor
types, making universal therapy unattainable.
We have previously also shown that the KIAA1549-BRAF fusions act as dimers and lead to
paradoxical activation of MAPK pathway with first generation RAF inhibitors, but are inhibited
by paradox breaker RAF inhibitors such as PLX8394 (A. J. Sievert et al., 2013). Recently, panRAF dimer inhibitors LY3009120 and BGB-283 have shown to be efficacious in RAF mutant
tumors (Henry et al., 2015; Peng et al., 2015; Tang et al., 2015) but how these drugs will impact
RAF fusions in PLGGs, is yet to be known. In addition to targeting upstream in the MAPK and
PI3K pathway, downstream inhibitors are also being evaluated in clinical trials. Phase I/II studies
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using the MEK1/2 inhibitor Selumetinib (AZD6244) for children with refractory/recurrent lowgrade gliomas is currently underway (ClinicalTrials.gov Identifier: NCT01089101 and
NCT01386450). Another phase II study is evaluating efficacy of single-agent Everolimus (or
RAD001, an mTOR2 inhibitor) for progressive pediatric low-grade gliomas (ClinicalTrials.gov
Identifier: NCT01734512). These studies are the first to test targeted inhibitors on children with
PLGGs and assess benefit over standard therapies. However, given the diversity in molecular
aberrations, such clinical studies need to be combined with comprehensive mutation screening to
ensure that PLGG patients are receiving personalized and effective therapy.

Novel therapeutic avenues: Epigenetic modulators
Epigenetic modifications are genomic changes that do not directly alter the DNA sequence,
including different mechanisms to affect the chemical properties of DNA or DNA packaging
proteins (histones). Oncogenic alterations in epigenetic modulators have been described for
several adult and pediatric tumors and are expanding the therapeutic and diagnostic toolkit for
human cancers.
Pediatric HGGs (Grade IV glioblastoma) display a range of somatic mutations in the histone 3
(H3) variant H3.3 encoded by the H3F3A gene, such as the K27M and G34R/V mutations
(Schwartzentruber et al., 2012; G. Wu et al., 2012). K27M mutations in H3.3 and another histone
variant H3.1 (HIST1H3B) are found in a large proportion of DIPGs, another devastating PHGG
with a dismal 5-year survival of less than 1% (Khuong-Quang et al., 2012; G. Wu et al., 2012).
Recent studies have demonstrated, for the first time, some efficacy of epigenetic therapy in
DIPGs. The multi-histone deacetylase (HDAC) inhibitor panobinostat showed surprising efficacy
in suppressing in vitro and in vivo DIPG mice xenograft growth (Grasso et al., 2015). Singleagent therapy with the histone demethylase inhibitor GSK-J4 can suppress DIPG cell lines
(Hashizume et al., 2014) but combination with panobinostat has shown synergistic inhibition of
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DIPG patient-derived lines (Grasso et al., 2015). Such epigenetic modifying therapies are opening
the preclinical realm for PHGGs where no targeted therapies exist.
PLGGs have been found to harbor H3F3A mutations in very rare cases of DAs and PAs (D. T. W.
Jones et al., 2013) with no other predominant epigenetic mutations. Furthermore, a group very
recently found pilocytic astrocytomas (PAs) to have distinct methylation signatures with
hypomethylation at multiple CpG sites, thereby suggesting uncontrolled gene transcription
(Jeyapalan et al., 2016). These findings suggest epigenetic modifications to precede gene
mutation/chromosomal rearrangement events that could then drive aberrant expression of PLGGspecific oncogenes. As such, epigenetic targeting could hold some promise for PLGGs but this
needs to be explored further. Our findings in aim 1 (chapter 2) with MYB-QKI will provide some
mechanistic insight into how epigenetic modification can mediate PLGGs.
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Tables and Figures
Figure 1.1

<1 year old

1-4 years old

5-9 years old

10-14 years old

Figure 1.1. Comparison of incidence rates of various childhood cancers by age. Plots
showing average annual age-related incidence of all primary brain and CNS tumors in
comparison to other cancers (leukemias, lymphomas and other solid tumors) in children. (a)
Infants (<1 Year Old), (b) Children 1–4 Years, (c) Children 5–9 Years, and (d) Children 10–14
Years (source CBTRUS 2007–2011, USCS 2007–2011)(Ostrom, de Blank, et al., 2015). Figure
adapted from Quinn T. Ostrom et al. Neuro Oncol 2015.
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Figure 1.2

Figure 1.2. Comparison of incidence rates and mortality rates between adult and
childhood cancers. Plots showing average annual age-related incidence of all primary brain and
CNS tumors in comparison to other cancers in (a) adults (+20 years old) and (b) children and
adolescents (0-19 years old) and mortality rates of all primary brain and CNS tumors as
compared to other common cancers in c) adults (age 20+ years) and d) children and adolescents
(age 0-19 years), CBTRUS statistical report: npcr and seer 2008-2012,USCS2008-2011b,NCVS
2008-2012 (Ostrom, de Blank, et al., 2015). Figure adapted from Quinn t. Qstrom et al. Neuro
oncol 2015.
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Figure 1.3

Figure 1.3. Classification of pediatric brain tumors by histology. Pie chart showing
distribution of all primary brain and CNS tumors by histology groupings in patients 0–14 Years,
N = 16,044 (CBTRUS 2007–2011) (Ostrom, de Blank, et al., 2015). Figure adapted from Quinn
T. Ostrom et al. Neuro Oncol 2015.
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Figure 1.4

Figure 1.4. Grade I and Grade II PLGGs classified on the basis of genetic/molecular
alterations. Mutations grouped into BRAF, FGFR, CRAF/RAF1, NTRK and MYB families
based on known oncogenes involved. Family of mutations can be further grouped within grade I
and grade II astrocytomas as low-grade tumor sub-types have distinct molecular signatures. AGangiocentric glioma, PXA- pleomorphic xanthoastrocytoma, GG- ganglioglioma.
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Figure 1.5

Figure 1.5. Simplified linear representation of the RAS/RAF/MEK/ERK (MAPK)
pathway. Upon receiving upstream signal from a growth factor activated receptor kinase, the
RAS protein is activated and leads to further stimulates downstream RAF kinases. NF1 serves to
negatively regulate RAS by preventing RAS activation leading to inhibition of the MAPK/ERK
pathway. Activated RAS proteins recruit RAF kinases to the membrane that leads to their
dimerization and consequent activation. RAF kinases then phosphorylate downstream MEK1/2
kinases, which then can phosphorylate ERK. The MAPK pathway eventually leads to
transcriptional changes in the nucleus that leads to cell proliferation and growth.
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Figure 1.6

Figure 1.6. Breakpoints in BRAF forming in-frame gene fusions in PLGGs. Linear
structure of BRAF gene on chromosome 7q34 showing breakpoints at exon 9 (KIAA1549-BRAF,
FAM131B-BRAF, MACF1-BRAF and RNF130-BRAF), exon 10 (KIAA1549-BRAF, FXR1-BRAF
and GNAI-BRAF) and exon 11 (KIAA1549-BRAF, CLC6-BRAF and MKRN1-BRAF) to form the
respective oncogenic gene fusions in PLGG patients. The conserved region 3 is retained in all
BRAF fusions (shown in green). BRAF point mutations (R506VLRK507, R509H and V600E) are
depicted in the ATP binding domain and activation segment of the kinase.
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Figure 1.7

Figure 1.7. Functional protein domains of (A) wild type QKI, MYB, RAF1 and NTRK2
proteins, (B) QKI fusions found in PLGG patient samples, MYB-QKI5/6, QKI-RAF1 and QKINTRK2 and the retained protein domains in truncated QKI and truncated MYB/ RAF1/ NTRK2.
DBD- DNA binding domain, TAD-trans-activation domain, NRD-negative-regulatory domain,
TM-transmembrane domain.
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The data in the following chapter are published in Nature Genetics 2016 Mar; 48(3):273-82.
doi: 10.1038/ng.3500. The Nature Publishing Group allows for authors to own copyright to their
primary research and data, so no permission was required from publisher, Kyle Vogan.
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CHAPTER 2: MYB-QKI rearrangements in angiocentric gliomas drive
oncogenicity through a tripartite mechanism
Summary
Angiocentric gliomas are pediatric low-grade gliomas (PLGGs) without known recurrent genetic
drivers. We performed genomic analysis of new and published data from 249 PLGGs including
19 Angiocentric Gliomas. We identified MYB-QKI fusions as a specific and single candidate
driver event in Angiocentric Gliomas. In vitro and in vivo functional studies show MYB-QKI
rearrangements promote tumorigenesis through three mechanisms: MYB activation by truncation,
enhancer translocation driving aberrant MYB-QKI expression, and hemizygous loss of the tumor
suppressor QKI. This represents the first example of a single driver rearrangement simultaneously
transforming cells via three genetic and epigenetic mechanisms in a tumor.

Introduction
Pediatric low-grade gliomas (PLGG) encompass a heterogeneous group of World Health
Organization grade I and II tumors that collectively represent the most common pediatric brain
tumor. PLGGs undergo frequent alterations in the MAPK pathway and in MYB family genes,
including MYBL1 and MYB (Ramkissoon et al., 2013; J. Zhang et al., 2013). Alterations in MYB
are heterogeneous; several fusion partners have been reported as rare events in PLGGs
(Ramkissoon et al., 2013). The frequency of specific alterations and associations with histological
subtypes are unknown.
Angiocentric Gliomas arise in the temporal lobe and share histologic features with astrocytomas
and ependymomas (Lellouch-Tubiana et al., 2005; M. Wang et al., 2005). We previously
identified one Angiocentric Glioma with deletion of the 3’ region of MYB (Ramkissoon et al.,
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2013) and one other Angiocentric Glioma has been reported to harbor a MYB-QKI rearrangement
(J. Zhang et al., 2013). However, the nature and incidence of MYB alterations in Angiocentric
Glioma has not been determined. Furthermore, oncogenicity of MYB family transcription factors
in the CNS and the mechanisms by which they contribute to gliomagenesis are yet to be defined.
To address these questions, we performed a combined analysis of newly generated and published
PLGG genomic datasets (D. T. W. Jones et al., 2013; Ramkissoon et al., 2013; J. Zhang et al.,
2013). We found MYB-QKI rearrangements to be the most common event involving a MYB
family member and to be specific to Angiocentric Gliomas. We also found that this
rearrangement contributes to oncogenicity through three mechanisms: generation of oncogenic
MYB-QKI, enhancer translocation that establishes an auto-regulatory feedback loop selectively
driving MYB-QKI expression, and partial loss of expression of QKI, a tumor suppressor gene.

Results
Angiocentric Gliomas exhibit recurrent MYB-QKI rearrangements
Previously published genomic analyses of PLGGs did not individually contain sufficient numbers
of rare histologic subtypes for statistical power to detect recurrent aberrations. To address this we
performed a combined genomic analysis of whole-genome sequencing (WGS) and/or RNAsequencing (RNA-seq) data from 172 PLGGs spanning ten histologic subtypes (Table 2.1),
including 145 published samples (D. T. W. Jones et al., 2013; J. Zhang et al., 2013) and 27 rare
PLGGs that are new to this study. We performed analyses of significantly recurrent somatic
genetic events across all samples with WGS or RNA-seq data (Fig. 2.1 and Tables 2.2 and 2.3).
We observed recurrent somatic alterations in 154 tumors (90%), including all 140 tumors subject
to WGS. Rearrangements or structural alterations were observed in 129 tumors (83%; Fig. 2.2a,
Table 2.1).
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Rearrangements involving MYB family members (MYB, MYBL1) were the second-most recurrent
alteration, affecting 16 tumors (10%), predominantly Diffuse Astrocytomas and Angiocentric
Gliomas (Fig. 2.1 and 2.2a). Six of seven Angiocentric Gliomas, including all tumors subject to
central pathology review, exhibited intra-chromosomal deletions resulting in MYB-QKI
rearrangements. The other Angiocentric Glioma, which was not centrally reviewed, contained a
MYB-ESR1 rearrangement.
Although MYB rearrangements have been described in PLGGs (Ramkissoon et al., 2013; J. Zhang
et al., 2013), we were struck by two novel findings: QKI was the most frequent fusion partner,
and MYB-QKI fusions were near-universal in Angiocentric Gliomas. For validation we identified
studied 12 additional Angiocentric Gliomas with only FFPE tissue using targeted assays. Nine
Angiocentric Gliomas were analyzed by FISH to detect MYB rearrangement or deletion (Fig.2.
2b), and three Angiocentric Gliomas were analyzed by WES and/or aCGH (Fig. 2.3). All 12
harbored MYB aberrations.
In total, all 19 Angiocentric Gliomas profiled by WGS, RNA-seq, WES, FISH, or aCGH
displayed MYB alterations, and in six of the seven cases in which its fusion partner could be
detected, MYB was fused to QKI. In tumors confirmed to harbor MYB-QKI, the genetic event
appeared to be present in the majority of cells, although evidence of heterogeneity (aberration in
~50% of tumor cells) was observed by FISH in 2/5 tumors with sufficient cells for quantitative
scoring.
MYB-QKI rearrangements appeared specific to Angiocentric Glioma. None of the 147 nonAngiocentric Gliomas profiled with WGS or RNA-seq exhibited MYB-QKI fusions (p<0.0001,
Fig. 2.2c). We also evaluated MYB alterations in an additional 65 PLGGs from two separate
cohorts: 10 non-Angiocentric Gliomas analyzed by FISH and 55 non-Angiocentric Gliomas
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evaluated by whole-exome sequencing (WES) and/or array CGH. Only one of these tumors
exhibited alterations of MYB (vs 19/19 Angiocentric Gliomas; p<0.0001) (Fig. 2.3 and Table
2.1). This tumor was designated not-otherwise-specified on research review but had been
diagnosed as Angiocentric Glioma at the referring institution. Five tumors evaluated by WES or
aCGH exhibited alterations of MYBL1; these were all Diffuse Astrocytomas. The FISH assays,
aCGH, and WES, though able to detect MYB alterations, were unable to characterize its fusion
partners.
All MYB-QKI rearrangements had breakpoints within intron 4 of QKI while the MYB breakpoint
varied from intron 9 to 15; all were predicted to express an in-frame fusion protein MYB-QKI
(Fig. 2.2d). We identified fusion mRNA transcripts by RNA-seq (Fig. 2d) and observed copynumber breakpoints in these genes from WGS data (Fig. 2.2e).
In the WGS/RNA-seq cohort we also observed rearrangements involving QKI but not MYB in
three supratentorial Pilocytic Astrocytomas (PAs), and rearrangements involving MYB or MYBL1
but not QKI in nine tumors, seven of which were Diffuse Astrocytomas. Across the entire cohort
of 172 tumors profiled with WGS and/or RNA-seq, 10% harbored alterations of either MYB
family members or QKI.
MYB and QKI have contrasting roles in cortical brain
MYB proteins are transcription factors characterized by highly conserved DNA-binding motifs.
First identified as v-myb (Klempnauer, Bonifer, & Sippel, 1986; Klempnauer et al., 1982; Ness,
Marknell, & Graf, 1989) the cellular proto-oncogene counterpart c-MYB is comprised of a Nterminus that contains helix-turn-helix (HTH) DNA binding motifs followed by a transcriptional
activation domain and a C-terminal negative regulatory domain (Sakura et al., 1989). Full-length
MYB is non-transforming or only weakly transforming in vitro (Gonda, Buckmaster, & Ramsay,
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1989), but C-terminal MYB truncations are oncogenic (Gonda et al., 1989; Grässer, Graf, &
Lipsick, 1991; Y. L. Hu, Ramsay, Kanei-Ishii, Ishii, & Gonda, 1991; Press, Reddy, & Ewert,
1994). MYB-QKI breakpoints in MYB intron 9 to 15 are predicted to result in C-terminal
truncation of MYB.
MYB is not expressed in the postnatal brain cortex, where Angiocentric Gliomas occur. We
examined RNA-seq data of normal tissues (G. Consortium, 2013) and found MYB expression to
be negligible in human brain cortex and substantially lower than MYB expression in colon, breast,
blood, esophagus, or skin (Fig. 2.4a). Likewise, immunohistochemistry of adult human frontal
cortex and white matter were negative for MYB (Fig. 2.4b and 2.4c); however we detected high
MYB expression in human fetal neural progenitor cells generated from the ganglionic eminence
at 22 weeks gestation (Fig. 2.4d and 2.4e).
In mice MYB is expressed in E14.5 neural progenitor cells of the ganglionic eminence subventricular region (Fig. 2.4f-i). In adult mice we detected expression in the ependyma/subventricular zone (Fig. 2.4j-k), consistent with previous reports of MYB expression in mouse
progenitor cells but not in cortical brain (Malaterre et al., 2008).
QKI encodes the STAR (Signal transduction and activation of RNA) RNA-binding protein
Quaking, which plays an essential role in oligodendroglial differentiation (Friedrich, 1974) and is
widely expressed in the nervous system. Deletions of QKI have been suggested to be oncogenic
in a number of cancers including glioblastoma (Yin et al., 2009), prostate cancer (Y. Zhao et al.,
2014), and gastric cancer (Bian et al., 2012). In copy-number analyses of 10,570 cancers within
the Cancer Genome Atlas (Zack et al., 2013), QKI was one of two genes in a deletion peak in
adult glioblastomas (Fig. 2.4l), renal clear cell, and cervical squamous cell carcinomas. It was
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also in larger peak regions of significant deletion in low-grade gliomas and bladder and
adrenocortical carcinomas. Focal QKI deletions were observed in over 10% of glioblastomas.
The MYB-QKI fusion protein is expected to retain the MYB N-terminal HTH DNA binding
motifs fused to the QKI C-terminus (Fig. 2.4m). The QKI N-terminal KH RNA-binding motif is
lost, while C-terminal alternative splice sites are preserved. The splice variant MYB-QKI5 retains
a nuclear localizing motif which is not present in the splice variant MYB-QKI6 (J. Wu, Zhou,
Tonissen, Tee, & Artzt, 1999). Fusions that contain only exons 1-9 of MYB also lose the MYB
negative regulatory domain (designated short variant).
The findings that both MYB and QKI are disrupted suggest that MYB-QKI rearrangements may be
oncogenic through the additive effects of alterations in both MYB and QKI. The lack of
expression of MYB in normal post-natal human cortical brain regions also suggests that the
rearrangement drives aberrant expression of the fusion allele. We therefore characterized
mechanisms through which MYB-QKI rearrangements may contribute to aberrant MYB-QKI
expression and evaluated the oncogenic potential of both genes.
MYB-QKI functions as a transcription factor
We performed genome-wide gene expression analyses of three independently-generated pools of
mouse neural stem cells (mNSCs) engineered to stably over-express MYB-QKI5, MYB-QKI6,
truncated MYB including exons 1-9 (MYBtrExon1-9), or eGFP. Relative to eGFP-expressing cells,
those expressing MYB-QKI5 and MYB-QKI6 exhibited significantly different expression of
1621 and 1947 genes, respectively, with 1029 genes overlapping (p<0.0001; Table 2.4). Gene-set
enrichment analysis revealed expression of either MYBtrExon1-9 or MYB-QKI was associated with
enrichment of signatures of MYB pathway activation (p<0.0001, Table 2.5).
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We defined a MYB-QKI gene expression signature comprising the 50 genes whose differential
expression correlated most with its expression (Fig. 2.5a). These genes include KIT and CDK6,
previously reported to be associated with MYB activation (Gao et al., 2014).
We performed chromatin immunoprecipitation with parallel sequencing (ChIP-seq) in mNSCs
expressing MYB-QKI, using an antibody which recognizes the N’ terminus of MYB and another
antibody against H3K27ac, which defines the location of enhancer regions. We found MYBQKI5 bound 3,672 sites across the genome (92% of these sites contain a MYB binding motif) and
H3K27ac bound 9,122 sites, with overlap at 1,907 sites (52% of MYB binding sites, p<0.0001)
(Fig. 2.5b). These findings are consistent with reports in T-cell ALL, where MYB binding was
highly correlated with H3K27ac defined enhancers (Mansour et al., 2014). We also identified
MYB-QKI binding to the endogenous Myb promoter (Fig. 2.6a).
MYB-QKI5 binding sites were located within 100kb of 88% (22/25) of upregulated genes in the
MYB-QKI signature but only 40% (10/25) of downregulated genes (p<0.001; Fig. 2.5c). Each of
the MYB-QKI binding sites associated with an upregulated gene was associated with an
H3K27ac enhancer peak, while only 70% of MYB-QKI binding sites at downregulated genes
overlapped enhancers (p=0.003).
The MYB-QKI fusion protein can activate transcription through binding of MYB consensus
binding motifs. We generated a luciferase-reporter construct using known MYB binding sites
from the target promoter mim-1 (Ness et al., 1989), and co-transfected this reporter with
MYBtrExon1-9, MYB-QKI, or full-length MYB, in 293T cells. We observed a slight induction of
mim-1 promoter activity with transfection with full length MYB compared to the control vector.
The greatest induction of mim-1 promoter activity was observed upon co-transfection with
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MYBtrExon1-9 or MYB-QKI (Fig. 2.5d and 2.6b), with MYBtrExon1-9 having the highest level of
activity.
Angiocentric Gliomas exhibited significantly higher expression of the MYB-QKI signature
relative to normal pediatric brain (p=0.001) and PLGGs without MYB-QKI alterations
(p=0.0011) (Fig. 2.5e). PLGGs exhibited increased expression of genes associated with MYB
pathway activation compared to normal brain (p=0.0003), but this was not specific to MYB-QKI
rearranged tumors, and was of lower magnitude than the difference observed with the MYB-QKI
signature (Fig. 2.6c).
MYB-QKI rearrangements drive aberrant expression of truncated MYB
Angiocentric Gliomas with MYB-QKI exhibit significantly higher MYB expression relative to
normal pediatric cortical brain (p=0.0062) or to PLGGs with BRAF or FGFR alterations (p=0.03)
(Fig. 2.7a). The MYB that is expressed is truncated and corresponds to the exons retained in the
rearranged MYB-QKI allele. Three Angiocentric Gliomas harbored MYB-QKI rearrangement
breakpoints between exons 9 and 10 of MYB. These exhibit increased expression of MYB exons
1-9 relative to PLGGs that do not harbor MYB-QKI (p<0.05), but minimal expression of the
remaining exons (Fig. 2.7b). These data support the selective, aberrant regulation of expression
of truncated MYB via MYB-QKI.
The MYB-QKI rearrangement results in enhancer translocation
Aberrant oncogene expression can result from enhancer translocation (Northcott et al., 2014). In
published H3K27ac enhancer profiles from normal human cortical brain samples (E. P.
Consortium, 2012), MYB is not associated with H3K27ac enhancer peaks, consistent with the
finding that MYB is not expressed. In contrast, QKI, which is expressed, is associated with several
H3K27ac peaks, including sequences at the 3’ end of QKI (Fig. 2.7c, d, e). The MYB-QKI
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rearrangement is predicted to bring these 3’ QKI-associated H3K27ac enhancer elements to
within only 15kb of the MYB promoter (Fig. 2.7e).
H3K27ac enhancer profiling of two human Angiocentric Gliomas expressing MYB-QKI
confirmed the presence of active enhancer elements that are translocated proximally towards the
MYB promoter (Figs. 2.8a and 2.9). ChIP-seq revealed multiple H3K27ac peaks associated with
3’ QKI, similar to the peaks observed in normal human brain, and in a BRAF-duplicated
supratentorial pilocytic astrocytoma. We also observed enhancers within 10kb of 3’ QKI and a
larger cluster of super-enhancers 100-500kb 3’ to QKI (Q3SE1 and Q3SE2). In Angiocentric
Gliomas with MYB-QKI, these enhancers are translocated proximally towards the MYB promoter.
We observed an aberrant enhancer associated with the MYB promoter in MYB-QKI defined
Angiocentric Glioma (Fig. 2.8a). Normal human cortical brain is not associated with H3K27ac
MYB-related enhancers, and indeed we did not observe formation of H3K27ac MYB enhancer
peaks in the Pilocytic Astrocytoma (Fig. 2.10). However, in both Angiocentric Gliomas, we
observed a large H3K27ac peak associated with the MYB promoter (M5E1). RNA-seq revealed
expression of the first nine exons of MYB corresponding to those retained in the rearrangement,
suggesting that the aberrant M5E1 enhancer is regulating expression of truncated MYB from the
rearranged allele. The lack of full-length MYB expression indicates the aberrant enhancer does not
regulate the remaining wild-type MYB allele.
We examined whether MYB-QKI was able to functionally activate the MYB promoter by creating
a luciferase-reporter construct possessing the human MYB-promoter (MYB-luc). We observed
significant induction of MYB promoter activity in U87 cells stably expressing MYB-QKI with
MYB-luc as compared to U87 cells containing MYB-luc or the promoter-less control luciferase
construct alone (Fig. 2.8c). This suggests MYB-QKI contributes to an auto-regulatory feedback
30

loop, possibly by binding to the MYB promoter. MYB-QKI activated the MYB promoter in two
additional cellular contexts (HEK 293T and NIH-3T3 cells, Fig. 2.11).
We predicted that enhancers in the QKI 3’ UTR could aberrantly activate the MYB promoter
when translocated, thereby further driving MYB-QKI expression. We cloned the proximal QKI
3’UTR enhancer sequence (Q3E1) upstream of the human MYB promoter in the MYB-luc
construct. Baseline activity of the Q3E1-MYB-luc promoter construct was higher than with MYBluc alone in U87 glioma cells (Fig. 2.8c), increasing activation by approximately 1.5 fold, a level
of activation shown to harbor biological relevance in other diseases (Menzel et al., 2007).
Expression of MYB-QKI with Q3E1-MYB-luc led to even higher activity, again consistent with
an auto-regulatory feedback loop in the presence of the fusion protein (Fig. 2.8c).
The MYB-QKI fusion protein is oncogenic
Expression of truncated MYB has previously been reported to be oncogenic (Gonda et al., 1989;
Y. L. Hu et al., 1991; Press et al., 1994). In mNSCs, overexpression of MYB exons 1-9 (short
variant) increased cell proliferation rates compared to eGFP controls (Figs. 2.12a and 2.11b),
while in NIH-3T3 cells overexpression of MYBtr (exons 1-15), but not full-length MYB, induced
tumors when injected into mouse flanks (Figs. 2.12b and 2.11b).

Furthermore mNSCs

expressing MYBtr induced diffuse gliomas on average 100 days post intracranial injection
(Figure 6e, f). These tumors expressed OLIG2 and GFAP in a subset of tumor cells, a pattern
similar to that observed in human diffuse gliomas (Fig. 2.11c).
To test whether MYB-QKI fusions are oncogenic, we stably expressed MYB-QKI5 and MYBQKI6 in mNSCs and NIH3T3 cells. In mNSCs, overexpression of either isoform led to
significantly increased proliferation compared to eGFP (Figs. 2.12c and 2.11b), p<0.0001.
Similarly both isoforms induced anchorage-independent growth in NIH-3T3 cells (Fig. 2.13a); in
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vivo, overexpression of both MYB-QKI5 and MYB-QKI6, but not full-length MYB, led to tumor
formation as flank xenografts (Fig. 2.12b). Intracranial injections of mNSCs overexpressing
MYB-QKI5 or MYB-QKI6 formed gliomas with infiltrating tumor cells with some evidence of
enhanced growth around vessels and a clustered growth pattern, features similar to Angiocentric
Glioma

and

distinct

from

the

histology

seen

adult

glioblastoma

models

(e.g.

Ink4a/ARF:EGFRvIII) (Bachoo et al., 2002). However these tumors differed from human
Angiocentric Gliomas in that they had high-grade features with frequent mitoses and marked
cytologic atypia (Fig. 2.12e). Immunohistochemical analysis showed diffuse GFAP expression
and a subset of OLIG2 positive tumor cells, a pattern similar to that seen in human Angiocentric
Gliomas (Fig. 2.11c).
In total, we established flank injections in 15 mice with NIH-3T3 cells over-expressing either
MYBtr or MYB-QKI (and five vector controls), and 29 intracranial injections of mNSC
expressing MYBtr or MYB-QKI (15 vector controls) (Fig. 2.13b). We observed flank tumors in
all 15 mice injected with NIH-3T3 cells over-expressing either MYBtr or MYB-QKI and five
intracranial tumors from mice injected with mNSCs expressing MYBtr or MYB-QKI. We did
not observe tumors in any vector controls. These data represent a significant enrichment of tumor
formation in cells expressing MYBtr or MYB-QKI (p<0.0001).
The MYB-QKI rearrangement disrupts QKI, a tumor suppressor
We were interested in understanding how disruption of QKI may contribute to oncogenicity in
tumors that harbor MYB-QKI. Exon-specific RNA-seq analysis of Angiocentric Gliomas with
MYB-QKI (n=4) showed reduced expression of QKI compared to PLGGs that harbor BRAF
alterations (n=5) (Fig. 2.14a). These data suggest that the MYB-QKI rearrangement may
contribute to tumor formation through reduced expression of QKI, a tumor suppressor gene.
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Indeed, suppressing wild-type Qk using shRNAs that target the first four exons of Qk led to
increased proliferation of mNSCs, with the greatest increase observed in the context of preexisting MYB-QKI expression. In mNSCs over-expressing MYBtr, MYB-QKI5 or MYB-QKI6,
suppression of wild type Qk was sufficient to increase proliferation within only three days of
suppression (Fig. 2.14b and 2.15a). The greatest effect was observed in cells overexpressing
MYB-QKI, despite a similar or lower degree of suppression of Qk in these cells compared to
those over-expressing eGFP or MYBtr. We did not observe increased proliferation within three
days in cells expressing eGFP, though we did observe a mild increase on day 5 (Fig. 2.15b).
These data suggest MYB-QKI overexpression and QKI suppression exert cooperative functional
effects.
Suppression of Qk by shRNAs in mNSCs expressing MYB-QKI6 led to differential expression of
309 genes relative to shLacZ (q<0.25, Table 2.6). QKI has been previously reported to regulate
expression of micro-RNAs (A. J. Chen et al., 2012; Y. Wang, Vogel, Yu, & Richard, 2013), and
we also observed upregulation of 10 miRNAs with suppression of wild-type Qk, including
Mir717 (Table 2.7). The mouse Qk isoform 7 is predicted to contain a miRNA regulatory
element (MRE) for Mir717 (Ji et al., 2013).
Angiocentric Gliomas exhibit molecular effects consistent with QKI suppression. In mNSCs, we
defined a signature consisting of the 50 genes whose expression was most correlated with Qk
suppression (Fig. 2.15c). This signature was significantly enriched in Angiocentric Gliomas
relative to normal brain (p<0.0001, Fig. 2.14c).
Taken together, our data suggest three mechanisms through which the MYB-QKI rearrangement
contributes to oncogenicity (Fig. 2.16). First, the alteration results in proximal translocation of
H3K27ac enhancers on 3’QKI towards the MYB promoter, resulting in MYB promoter activation.
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Second, the MYB-QKI fusion protein that is expressed is oncogenic, functions as a transcription
factor, and exhibits the ability to bind to and activate the MYB promoter, resulting in an autoregulatory feedback loop. Third, hemizygous loss of QKI results in suppression of QKI, which
functions as a tumor suppressor gene. Thus disruption of both MYB and QKI appear to contribute
to tumor formation in a co-operative manner.

Discussion
We describe MYB-QKI as a novel recurrent diagnostic fusion in Angiocentric Glioma. It also
represents the first example of a single driver translocation of two genes resulting in the aberrant
expression of an activated oncogenic fusion protein which then participates in an auto-regulatory
feedback loop, proximal translocation of enhancer elements regulating fusion-gene expression,
and simultaneous functional loss of a tumor suppressor gene.
We found MYB-QKI to be a defining event in Angiocentric Glioma. This has important
implications for treatment and diagnosis of this disease. The tight association of the translocation
with this histology supports pathologic classification of Angiocentric Glioma as a separate
biological entity. We propose that the presence of this fusion should be considered diagnostic of
Angiocentric Glioma. This could aid in distinction of Angiocentric Glioma from tumors with
higher potential for recurrence or require further treatment, such as IDH-mutant diffuse gliomas
or ependymomas.
MYB-QKI expression was sufficient to reproducibly generate intracranial tumors. Angiocentric
Gliomas are WHO grade 1 tumors and exhibit a very low mitotic index. Successful models of
low-grade pediatric or adult gliomas are rare across all histologies. The low penetrance in mNSCs
(5 tumors in 29 attempts) relative to high-grade glioma models (e.g. EGFRvIII and Ink4a/Arf -/-
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NSCs) (Bachoo et al., 2002) suggests genetic drivers of low-grade gliomas may be borderline
sufficient for transformation.
Although the development of small molecule inhibitors to target MYB directly is likely to be
challenging, MYB-QKI transcriptional targets such as KIT or CDK6 can be targeted. The
association of MYB-QKI with H3K27ac enhancer elements also raises the possibility of
therapeutically inhibiting its effects through indirect mechanisms, such as BET-bromodomain
(Pratiti Bandopadhayay et al., 2014; Delmore et al., 2011) or CDK7 inhibition (Chipumuro et al.,
2014).
Adenoid cystic carcinomas harbor MYB-NFIB alterations (D&apos;Alfonso et al., 2014; Marta
Persson et al., 2009; Stephens et al., 2013). Like MYB-QKI, MYB-NFIB also results in high levels
of MYB expression, although the mechanism underlying this, the functional role of NFIB, and
oncogenicity of MYB-NFIB remain undefined.
We observed an additive effect of Qk suppression with MYB-QKI over-expression, confirming
QKI as a tumor suppressor and suggesting cooperation between its loss and expression of MYBQKI. Recent studies indicate a diversity of roles for QKI in cancer, including altered splicing
events (Danan-Gotthold et al., 2015) and a role in epithelial-mesenchymal transition via
regulation of circular RNAs (Conn et al., 2015). QKI regulates expression of genes implicated in
cancer (Lu et al., 2014), and microRNA processing (Ji et al., 2013). Further investigation is
required to evaluate mechanisms of cooperativity between QKI suppression and MYB-QKI
expression.
Angiocentric Gliomas exhibit haploinsufficiency of QKI while GBMs demonstrate biallelic loss.
One explanation may be that complete loss of QKI exerts negative selection in the developing
brain. This is supported by the essential role of QKI in oligodendrocytic differentiation.
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Haploinsufficiency may also account for the lower-grade nature of Angiocentric Glioma
compared to GBM.
Pediatric tumors are characterized by simple genomes with single driver alterations (Crompton et
al., 2014; Kieran et al., 2012). Our findings that one rearrangement contributes to oncogenicity
through multiple mechanisms may be applicable to a large number of pediatric tumors.

Materials and Methods
Ethics statement
Ethics approval was granted by relevant human IRB and/or animal research committees (IACUC)
of Dana-Farber Cancer Institute (DFCI), Boston Children’s Hospital, The Broad Institute and
Children’s Hospital of Philadelphia (CHOP). IRB approval from all institutions was obtained, and
all patients provided informed consent prior to collection of samples or were analyzed as deidentified samples with specific IRB waiver of informed consent.
Whole-genome sequencing and processing
PLGGs and normal controls from CBTTC/CHOP and DFHCC/PLGA Consortium were
sequenced at BGI@CHOP, and The Broad Institute of MIT and Harvard. DNA was randomly
fragmented, and libraries prepared for paired-end sequencing on an Illumina HiSeq 2000.
Sequencing files from recently published PLGG datasets were accessed (D. T. W. Jones et al.,
2013; J. Zhang et al., 2013). Read pairs were aligned to reference genome hg19 (Build 37) using
the Burrows-Wheeler Aligner (bwa) with options −q 5 −l 32 −k 2 −o 1 (H. Li & Durbin, 2009).
Reads were sorted by coordinates, normalized, cleaned and duplicates were marked using
SAMtools and Picard. Base quality score assignments were recalibrated to control for biases due
to flow cell, lane, dinucleotide context and machine cycle using the Genome Analysis Toolkit
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(GATK) (McKenna et al., 2010). Copy-number alterations were evaluated using SegSeq (Chiang
et al., 2009). GISTIC2 was used to identify recurrent copy-number alterations (Beroukhim et al.,
2007; Beroukhim et al., 2010; Zack et al., 2013). Somatic point mutations and short indels were
called using Mutect (Cibulskis et al., 2013) and IndelLocator, and visual inspection in IGV
(Robinson et al., 2011). Mutsig (version 2.0) (Lawrence et al., 2014) was applied to detect
significantly recurrent mutations. Rearrangements and breakpoints were identified using dRanger,
BreakPointer (Yotam Drier et al., 2013) and visual inspection. All analyses were performed
within Firehose (M. A. Chapman et al., 2011). This work was conducted by our collaborating lab,
Rameen Beroukhim and Keith Ligon at Dana-Faber Cancer Institute.
RNA-sequencing and analysis pipeline
Following RNA extraction (RNeasy, Qiagen), library construction was performed using a nonstrand specific Illumunia TruSeq protocol. Flowcell cluster amplification and sequencing were
performed according to the manufacturer’s protocols using HiSeq 2000/2500, with a 76 bp
paired-end run including an eight-base index barcode read. RNA-sequencing files were
downloaded from published datasets (D. T. W. Jones et al., 2013; J. Zhang et al., 2013). RNA-seq
bam files were transformed to fastq files using the Picard SamToFastq algorithm. Raw paired-end
reads were aligned to the reference genome hg19 and preprocessed using PRADA (Pipeline for
RNA-sequencing Data Analysis) (Torres-García et al., 2014). We used PRADA within Firehose
to determine gene-expression levels, exon expression levels, quality metrics, and for detection of
fusion transcripts. BAM files were also assessed by visual inspection. This work was conducted
in collaboration with Rameen Beroukhim and Keith Ligon’s labs at Dana-Faber Cancer Institute.
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Array CGH
DNA was extracted from archival FFPE samples and aCGH performed as previously described
(Craig et al., 2012; Ramkissoon et al., 2013). GC-normalized copy-number data was cleaned of
known germ-line copy-number variations and circular Binary Segmentation was used to segment
the copy-number data (α = 0.001, undo.splits = sdundo, undo.SD = 1.5, minimum width = 5).
This work was conducted by Rameen Beroukhim and Keith Ligon labs at Dana-Faber Cancer
Institute.
Whole exome sequencing
WES was performed from FFPE samples (without matched control). These samples were used to
confirm driver alterations identified by the WGS. DNA was extracted using the QIAGEN DNA
Blood and Tissue kit. Libraries with a 250 bp average insert size were prepared by Covaris
sonication, followed by double-size selection (Agencourt AMPure XP beads) and ligation to
specific barcoded adaptors (Illumina TruSeq) for multiplexed analysis. Exome hybrid capture was
performed with the Agilent Human All Exon v2 (44 Mb) bait set.
Sequence data were aligned to the hg19 reference genome with the Burrows-Wheeler Aligner
with parameters [-q 5 -l 32 -k 2 -t 4 -o 1]. Aligned data were sorted, duplicate-marked, and
indexed with Picard tools. Base-quality score recalibration and local realignment around
insertions and deletions was achieved with the Genome Analysis Toolkit.
Mutations were called with MuTect, filtered against a panel of normals, and annotated to genes
with Oncotator. Likely germline SNPs were removed by filtering against the Exome Sequencing
Project (ESP) and Exome Aggregation Consortium (ExAC).
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This work was conducted by Rameen Beroukhim and Keith Ligon labs at Dana-Faber Cancer
Institute.
Histological assignment
Histologic subtype assignments were according to previously published data. Samples not
previously published were centrally reviewed and classified by a board-certified neuropathologist
(K.L.L., S.S, or S.R.) using W.H.O. 2007 criteria.
MYB FISH
FISH was performed as previously described (Firestein et al., 2008) using five micron FFPE
tissue sections and Homebrew probes RP11-63K22 (5’ to MYB; directly labeled in
SpectrumOrange) and RP11-170P19 (3’ to MYB; directly labeled in SpectrumGreen) that map to
6q23.3.

MYB status was assessed in 50 tumor nuclei per sample.

A CEP6 aqua probe

(Invitrogen) mapping to the centromeric region of chromosome 6 was co-hybridized as a control.
This work was conducted by the Keith Ligon lab at Dana-Faber Cancer Institute.
Immunohistochemistry
Diaminobenzidine (DAB), bright-field staining was performed according to standard protocols on
five-micron thick paraffin sections. Heat and 10 mM sodium citrate buffer (pH 6.0) were used
for antigen retrieval for the MYB (Abcam for human tissue, Bethyl Laboratories for mouse
tissue), OLIG2 (Chemicon) and GFAP (Millipore) antibodies. Counterstaining for nuclei was
performed using Mayer’s hematoxylin stain and coverslips were mounted with Permount (Fisher
Scientific). Sections from the left occipital pole of a normal adult brain autopsy were used to
assess MYB levels. This work was conducted by the Keith Ligon lab at Dana-Faber Cancer
Institute.
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Analysis of QKI alterations in TCGA samples.
GISTIC 2.0 analyses were performed across 10,570 tumor samples from 31 lineages from The
Cancer Genome Atlas (TCGA), as previously described ack 20 (Zack et al., 2013). This work was
conducted by the Beroukhim lab at Dana-Faber Cancer Institute.
Analysis of gene expression in normal tissues.
RNA-sequencing of normal pediatric brain samples was accessed from the BRAINSPAN Atlas of
the human developing brain and processed as previously described (Bergthold et al., 2015). MYB
expression levels from RNA-sequencing obtained from normal autopsy tissues were downloaded
from the GTEx consortium (G. Consortium, 2013). Expression levels were compared using
ANOVA and t-tests. p-values <0.05 were considered significant. This work was conducted by the
Beroukhim lab at Dana-Faber Cancer Institute.
Vector construction and generation of NIH3T3 stable lines
MYB-QKI5 and MYB-QKI6 constructs were synthesized as Gateway compatible entry clones.
MYBtr constructs were generated via PCR mutagenesis using MYB-QKI fusions as templates.
Full-length MYB and QKI constructs were purchased as gateway entry clones from
PlasmID/DF/HCC DNA Resource Core. MYB-QKI5 and MYB-QKI6, MYBtr, full-length MYB
and QKI constructs were sub-cloned into a Gateway-compatible N-MYC-tagged pMXs-Puro
Retroviral Vector (Cell Biolabs). Platinum-E retroviral packaging cells (Cell BioLabs) were used
to generate retrovirus as per manufacturer protocols. NIH3T3 cells were infected with retrovirus
containing media for 6 hours and puromycin selection commenced 48 hours post infection. Stable
expression of MYC-tagged proteins was confirmed via western blot analysis (anti-MYC HRP
1:5000 (Invitrogen), anti-MYB antibody 1:5000 (Abcam) and anti-QKI 1:1000 (Bethyl Lab).
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Soft Agar Colony Formation Assays and quantification
Anchorage-independent growth of NIH3T3 cells was assayed as previously described (A. J.
Sievert et al., 2013) with the following modifications: NIH3T3 cells expressing each of the MYBQKI5, MYB-QKI6, MYBtr, full-length MYB and full length QKI proteins and retroviral vector
control were plated in 0.7% agar with DMEM and DBS in 96 well plates (in triplicates). Cell
colonies were allowed to form for two weeks and images were taken. Images were analyzed using
ImageJ and colonies with area greater than 500 pixels quantified.
Generation of reporter construct containing MYB promoter and enhancer constructs
To assess the effect of candidate enhancer regions on MYB promoter activity, the human MYB
promoter sequence (shown below) was cloned into the pLightSwitch_Prom Vector (Active Motif)
that contains a multiple cloning site upstream of a Renilla luciferase reporter gene (RenSP)
without a promoter. The MluI/BglII site on pLightSwitch_Prom Vector was used to clone the
MYB promoter sequence (Table 2.9) and the MluI site was further used to clone candidate
enhancer regions upstream of the MYB promoter. The human QKI 3’UTR enhancer sequences
(hg18 chr6:163920360-163920809 and chr6:163921548-163921972) were synthesized by
Invitrogen and cloned into the reporter constructs as described above. The LightSwitch™
Random Promoter Control 1 (Active Motif) containing a 1 kb non-conserved, non-genic and nonrepetitive fragment from the human genome cloned upstream of the RenSP luciferase reporter
gene was used as a negative control. A housekeeping gene promoter vector, LightSwitch™
ACTB Promoter Control, was used as positive control for all assays. The luciferase reporter
constructs containing either the MYB promoter or MYB promoter with enhancers were
transfected into U87 glioma line (or MYB-QKI stably expressing U87 line) using Lipofectamine
3000 (n=5), or co-transfected with MYB-QKI or vector control into HEK 293s via Lipofectamine
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2000 (Invitrogen), or in NIH3T3/ MYB-QKI stably expressing NIH-3T3 lines using PolyFect
(Qiagen). Luciferase activity was quantified 24 hours post transfection using the LightSwitch™
Luciferase Assay Reagent (Active Motif) according to the manufacturer’s protocol.
mim-1 reporter construct generation and MYB transactivation assays Luciferase reporter
constructs containing a consensus DNA-binding sequence for c-MYB were generated. The
reporter construct was designed using the core MYB recognition element (MRE) consensus
sequence PyAAC(G/T)G which is present in the mim-1 gene promoter, a previously described
MYB target (Ness et al., 1989). Double stranded oligos were generated by annealing primers
mim-1 forward and mim-1 reverse (Table 2.9). The annealed oligo was ligated into
pGL4.10[luc2] vector (Promega) digested with XhoI and HindIII. The pRL Renilla Luciferase
Reporter Vector (Promega E2261) served as an internal control in all assays. The mim-1 reporter
construct and pRL renilla vector (ratio 30:1) were co-transfected into HEK-293 along with
indicated fusions or controls via Lipofectamine 2000. Luciferase activity was quantified 24 hours
post transfection using the Dual-Luciferase Reporter Assay System (Promega) according to
manufacturer’s protocol.
Cell lines
NIH3T3, 293T and U87 MG cell lines were obtained directly from ACTT and not reauthenticated. All cell lines were routinely tested (at least every three months) for mycoplasma
infection.
Generation of neural stem cells.
Embryonic murine neural stem cells (mNSC) were derived from C57BL6 wild-type E14.5 dpc
mouse embryos (purchased from Taconic) as previously described (Reynolds & Weiss, 1992).
mNSCs were maintained in culture media with 1:1 Dulbecco modified Eagle medium (Gibco)
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and neural stem cell media (Gibco) supplemented with B27 (Gibco), EGF (02653, Stem Cell),
FGF (GF003, Millipore), and Heparin (07980, Stem Cell). This work was conducted by the
Beroukhim lab at Dana-Faber Cancer Institute.
Overexpression of transcripts in mouse neural stem cells
293T cells were transfected with 10 μg lentiviral pLEX307 expression vectors (gift from David
Root, Addgene plasmid #41392) with packaging plasmids encoding PSPAX2 and VSVG using
Lipofectamine. Lentivirus-containing supernatant was collected 48 hour after transfection, pooled
and concentrated (ultrafiltration). Target neural stem cells underwent infection using a spin
protocol (2000rpm for 120 minutes at 30C with no polybrene). Puromycin selection (0.5mcg/ml)
commenced 48 hours after infection. This work was conducted by the Beroukhim lab at DanaFaber Cancer Institute.
ShQk experiments and proliferation assays
Lentiviral vectors (pLKO) encoding shRNAs specific for mouse Qk, targeting sequences in the
first four exons of Qk, and the control shLacZ were obtained from The RNAi Consortium (Table
9). Lentivirus was produced by transfection of 293T cells with vectors encoding each shRNA
(10 μg) with packaging plasmids encoding PSPAX2 and VSVG using Lipofectamine (Invitrogen,
56532).

Lentivirus-containing supernatant was collected 48 hours after transfection, and

concentrated. Target mNSC underwent infection using a spin protocol (2000rpm for 120 minutes
at 30C with no polybrene). Cells were placed into proliferation assays 48 hours after infection.
This work was conducted by the Beroukhim lab at Dana-Faber Cancer Institute.
Cell Proliferation Assays
1000 cells/well were plated in 96-well plates, with five replicates. Cell viability was measured by
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assessing ATP content using Cell Titre-Glo (Promega). Mean

SEM was calculated. This work

was conducted by the Beroukhim lab at Dana-Faber Cancer Institute.
Western immunoblotting
Cells were lysed and subjected to SDS-PAGE gradient gels as previously described (Pratiti
Bandopadhayay et al., 2014). Blots were probed with antibodies against MYB (ab45150,
Abcam), QKI (A300-183A, Bethyl Laboratories) and actin (sc-1615, Santa Cruz).
RNA extraction and Real-Time RT-PCR
RNA was extracted with the RNeasy kit (Qiagen). cDNA was synthesized from 1µg RNA using
High Capacity RNA to cDNA kits (Applied Biosystems). Real-time RT-PCR was performed as
previously described (Pratiti Bandopadhayay et al., 2014). Primers for MYB, QKI and -actin are
listed in Table 9. Samples were amplified in triplicate and data analyzed using the

CT method.

This work was conducted by the Beroukhim lab at Dana-Faber Cancer Institute.
Gene-expression analysis of neural stem cells expressing MYB-QKI
RNA was extracted from three independently generated pools of mNSC expressing one of eGFP,
MYBtr, MYB-QKI5, MYB-QKI6 or QKItr.

Gene expression profiles were assayed using

Affymetrix Mouse Gene 2.0 ST microarrays (Affymetrix, Santa Clara, CA). CEL files were
RMA normalized (Bolstad, Irizarry, Astrand, & Speed, 2003). Comparative marker selection
analysis (Gould, Getz, Monti, Reich, & Mesirov, 2006) was performed in GenePattern using
default settings. Genes with p-value <0.05 and q-value <0.35 were considered significant. GSEA
was performed using the C2 (CP) gene sets (MSigDB). Genesets with nominal p-values <0.05
were considered significant. The MYB-QKI signature was defined using the ClassNeighbours
module of GenePattern (default settings). This work was conducted by the Beroukhim lab at
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Dana-Faber Cancer Institute.
Antibody optimization and ChIP-seq
We systematically determined the antibody and concentrations that produce the highest signal to
noise ratio for MYB ChIP-seq using our automated ChIP-seq methodology (Etchegaray et al.,
2015; Garber et al., 2012). We tested two MYB antibodies: abcam ab45150 and Sigma
SAB4501936. Abcam45150 has been previously used to ChIP MYB (Mansour et al., 2014). We
split the sheared chromatin between 3 ratios of antibody/chromatin (0.5µl, 1 µl and 5 µl of each
antibody/1,000,000 cells), and performed ChIP-seq as previously described (Garber et al., 2012).
As a positive control, we included an antibody targeting H3K27ac (Cell Signaling Technologies
D5E4, optimized at 1 µl/1,000,000 cells). We found 1µl ab45150/1,000,000 cells to be optimal.
Results from the MYB ChIP-seq were validated in three ways. First, we performed MYB ChIPseq in K562 cells and confirmed enrichment at genes reported to be target genes in a prior study
of these cells (Fig. 2.17) (Bengtsen et al., 2015). Second, we used Homer (Heinz et al., 2010) to
perform an unbiased motif analysis across peaks identified (peak detection threshold of ) p1-e6))
in mNSC over-expressing MYBQKI, and identified MYB motifs to be the most enriched motifs
across all peaks (p= 1e-681) (Fig. 2.18a). We observed 92% of all peaks (p threshold 1e-6,
3392/3672 peaks) to contain a MYB motif (Fig. 2.18b, Table 2.10). Enrichment of MYB motifs
was significantly higher in data generated with the MYB antibody (p= 1e-681) compared to those
generated from enrichment with H3K27ac (p=1e-25). Third, we compared our results from
mNSCs to other published MYB ChIP-seq results. We determined whether MYB bound genes
identified in our study (MYB peaks containing a MYB motif) were overlapping target genes
reported in these studies, using a Chi-Square test with Yates Correction. We observed significant
enrichment (p<0.0001; Fig. 2.18c) (Quintana, Liu, O&apos;Rourke, & Ness, 2011; L. Zhao et al.,
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2011). Of 2879 genes identified in our set 20% (Zhao) and 42% (Quintana) were also identified
in these studies.
ChIP libraries were indexed, pooled and sequenced on Illumina Hi-seq-2000 sequencers. Raw
data was aligned to the mouse reference genome MM9 using Picard tools. Raw sequencing data
was mapped to the reference genome using bowtie2 version 2.2.1 with parameters -p 4 -k 1.
Peaks were called using MACS version 1.4.2 over an input control. A p-value threshold of
enrichment of 1E-6 was used. Density of genomic regions was calculated using
bamliquidator_batch, version 1.1.0. Reads were extended 200-bp and normalized to read-density
in units of reads per million mapped reads per bp (rpm/bp). To calculate genome-wide overlap,
all enriched H3K27ac peaks were extended 5kb in each direction, divided into 50 bins, and read
density was calculated in each bin. Density was normalized to the largest value observed in each
experiment genome-wide and plotted as a heat map. Peaks and alignments were converted to
TDFs by IGV tools and visualized by IGV. Bed files of published ChIP-seq data of H3K27ac
chromatin maps from normal brain (Zhu et al., 2013) were downloaded and visualized in IGV.
ChIP-seq enriching for H3K27ac was performed on human pediatric low-grade gliomas by
Active Motif as recently described (Northcott et al., 2014). Analysis was performed as above
using a p-value threshold of enrichment of 1E-5. Super-enhancer analysis was performed as
previously described (Chapuy et al., 2013).
This work was conducted by the Ligon and Beroukhim labs at Dana-Faber Cancer Institute.
In vivo experiments
Mouse flank tumor studies with NIH3T3 Stable Cell Lines: NIH3T3 cell lines were injected
subcutaneously into the flanks of NSG mice (5 mice for each cell line). Mice were 6-10 weeks of
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age, with equal representation of male and female mice. Tumor growth was measured biweekly.
Ellipsoid tumor volume was calculated using the formula: volume = 1/2(length × width2).
Intracranial mouse injections: Neurospheres were dissociated and resuspended at 100,000 viable
immunocompromised ICR-SCID
mice. Animals were monitored and sacrificed at the onset of neurological symptoms. Brains
were subjected to routine histological analysis.

Tumors were scored as present based on

identification of atypical cells by a neuropathologist. 4-6 week old, male IcrTac:ICRPrkdc-Scid
mice from Taconic were used. A total of 44 mice were used. This MNSC work was conducted by
the Ligon and Beroukhim labs at Dana-Faber Cancer Institute.
Mouse injections were not randomized or blinded. Sample size was not predetermined.
Qualitative assessment of tumorogenicity was the primary outcome measure. Neuropathologists
were blinded to group allocation.
Statistical analysis
For statistical analysis (unless otherwise described), p values were calculated using Fisher’s, Ttests or Pearson’s as appropriate. ANOVA with correction was used for comparison of multiple
groups. Log-rank (Mantel-Cox) survival analysis was performed for animal studies and Kaplan
Meier curves generated. Error bars shown depict standard error of the mean.
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Tables and Figures
Table 2.1. PLGGs included in analysis including tumor demographics, method of
profiling and driver alterations identified.
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S2.xlsx

Table 2.2. GISTIC amplification peaks
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S3.txt

Table 2.3. GISTIC deletion peaks
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S4.txt

Table 2.4. Differentially expressed genes in neural stem cells expressing eGFP,
MYBtr or MYB-QKI
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S5.xlsx

Table 2.5. Gene-Set Enrichment Analysis in neural stem cells expressing eGFP,
MYBtr or MYB-QKI
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S6.xls

Table 2.6. Differentially expressed genes in neural stem cells expressing MYB-QKI
with shLacZ or shQk
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S7.xlsx

Table 2.7. miRNAs that are differentially expressed in mNSCs expressing MYBQKI following suppression of wild type Qk
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S8.xlsx

Table 2.8. MYB promoter sequence and shQk clones used in experiments
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S9.xlsx
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Table 2.9. PCR primers used in experiments.
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S10.xlsx

Table 2.10. ChIP-seq peaks (p1e-6) identified following MYB ChIP-seq in mNSC
over-expressing MYBQKI5. Peaks that contain a MYB binding motif (fragment size
used in analysis = 200) are shown in the columns labeled MYBL1 or MYB.
Online link to table: http://www.nature.com/ng/journal/v48/n3/extref/ng.3500-S11.xls
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Figure 2.1. Significant regions of recurrent copy-number alterations in PLGG. GISTIC q
values for amplifications (left) and deletions (right) are plotted across the genome.
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Figure 2.2

Figure 2.2. Genomic analysis of 172 WGS and/or RNA-seq of PLGGs reveals a recurrent
rearrangement involving MYB and QKI in Angiocentric Gliomas. (a) Driver alterations
were identified in 154 of 172 PLGGs profiled with WGS and/or RNA-seq. Histological subtypes
include Pilocytic Astrocytoma (PA). Pilomyxoid Astrocytoma (PMA), Angiocentric Glioma
(AG), Oligodendroglioma (OD), Diffuse Astrocytoma (DA), Dysembryoplastic Neuroepithelial
Tumor (DNT), Ganglioglioma (GG), Pleomorphic Xanthoastrocytoma (PXA), and PLGG not
otherwise specified (NOS). Tumors for which histology is unavailable are designated NA. (b)
FISH using probes flanking MYB reveal three patterns in PLGG: disomy, MYB rearrangement,
or 3’ MYB deletion. Scale bars = 5 microns. (c) Frequency of MYB alterations or MYB-QKI
rearrangements in Diffuse Astrocytoma and Angiocentric Glioma. p value represents enrichment
of MYB-QKI rearrangements in Angiocentric Glioma. MYB-QKI alterations were identified with
WGS alone (n=1), WGS and RNA-seq (n=2) or RNA-seq alone (n=3). (d) Breakpoints observed
in MYB and QKI in Angiocentric Gliomas. Sequence across the breakpoints as determined by
RNA-seq is shown for each rearrangement. (e) Copy-number profiles from WGS data of MYB
and QKI in three Angiocentric Gliomas.
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Figure 2.3
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Figure 2.3. Co-mut plot of driver alterations identified in 54 PLGGs profiled with WES
and/or array CGH.
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Figure 2.4

Figure 2.4. Alterations of MYB and QKI occur frequently in human cancers. (a)
Expression of MYB (mean ± SEM) in normal human colon (n=12), breast (n=27), whole blood
(n=51), esophagus (n=38), skin (n=25), and brain cortex (n=47). (b) MYB immunohistochemistry
on human adult frontal cortex. Scale bar = 100 microns (c) MYB immunohistochemistry on
human adult white matter. Scale bar = 100 microns (d) Hematoxylin and eosin (H&E) on human
fetal neural stem cells generated from the ganglionic eminence at 22 weeks gestation. Scale bar =
100 microns (e) MYB immunohistochemistry demonstrates positive staining in a subset of cells.
Scale bar = 100 microns (f) Sagittal section from embryonic 14.5 days post coitus (E14.5) mouse
brain. Scale bar = 500 microns. (g) H&E of E14.5 ganglionic eminence (ge) including ventricular
(ge-vz) and subventricular (ge-svz) zones. Scale bar = 50 microns. (h) Immunohistochemical
analysis for MYB on the E14.5 ganglionic eminence. Scale bar = 50 microns. (i) MYB
immunohistochemistry demonstrates positive staining in a subset of cells subventricular zone (gesvz) but not the ventricular zone (ge-vz). Scale bars = 50 microns. (j) H&E from periventricular
region of adult mouse brain. Scale bar = 100 microns. (k) Immunohistochemistry for MYB
demonstrates positive cells (arrows) in the ependymal/SVZ layer. Scale bars = 100 microns. (l)
(Left panel) Significance of deletions (x-axis) and (middle and right panels) heatmaps indicating
copy-number profiles of individual tumors, for chromosome 6q of adult Glioblastomas profiled
by TCGA. (m) Predicted structure of the MYB-QKI fusion protein, with fusion of the C-terminus
of QKI to truncated MYB. TAD denotes transactivating domain. The C-terminus of QKI includes
QUA2 domains and undergoes alternate splicing. MYB-QKI5 retains a nuclear localizing
sequence (NLS) that is lost in MYB-QKI6. Two variants of MYB-QKI are depicted (Short and
Long) corresponding to the breakpoint of MYB within the rearrangement.
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Figure 2.5
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Figure 2.5. MYB-QKI functions as a transcription factor, and its molecular effects are
observed in Angiocentric Gliomas. (a) MYB-QKI expression signature in mouse neural stem
cells relative to cells expressing eGFP controls. (b) Heatmap of H3K27ac and MYB-QKI levels
at MYB-QKI regions. Each row shows +/-5 kb centered on MYB-QKI peaks. These regions are
rank-ordered by MYB-QKI signal. Scaled intensities are in units of rpm/bp (c) ChIP-seq binding
of MYB-QKI to genes included in the MYB-QKI gene expression signature. (d) mim-1 reporter
induction following transfection of MYBtr, MYB-QKI5, MYBQKI6 or full length MYB in 293T
cells. Values shown represent mean of three independent measurements ± SEM. (e) Expression of
MYB-QKI signature in normal pediatric brain samples, PLGGs without MYB-QKI, or
Angiocentric Gliomas with MYB-QKI. Values represent mean expression of signature in tumors
± SEM. Expression of signature within each tumor is the sum of rpkm of each gene in the
signature.
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Figure 2.7. Angiocentric Gliomas exhibit aberrant expression of MYB-QKI due to
H3K27ac enhancer translocation and an auto-regulatory feedback circuit in which
MYB-QKI binds to the MYB promoter. (a) MYB RPKM expression levels of MYB-QKI
tumors (n=5) relative to normal brain (n=10) or BRAF or FGFR driven PLGGs (n=10). Values
shown represent mean ± SEM. (b) Exon-specific expression of MYB in Angiocentric Gliomas
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are shown. (d) H3K27ac binding to enhancer elements within MYB and QKI in human frontal and
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data.
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Figure 2.8. Human Angiocentric Gliomas exhibit H3K27ac enhancer translocation with
an aberrant enhancer associated with the MYB promoter. (a) H3K27ac enhancer peaks in
proximity to MYB and QKI in a BRAF-duplicated Pilocytic Astrocytoma (top) and MYB-QKI
Angiocentric Glioma (lower). Q3E1 is an enhancer associated with the 3’UTR of QKI. Two
super-enhancer clusters (Q3SE1 and Q3SE2) are located within 500kb of QKI. Angiocentric
Gliomas are associated with aberrant enhancer formation at the MYB promoter (M5E1), which is
not detected in the BRAF driven pilocytic astrocytoma. The breakpoints for the MYB-QKI
rearrangement are between exons 1-9 MYB and 5-8 QKI. Expression as determined by RNAsequencing is depicted for the MYB-QKI Angiocentric Glioma. (b) 3’ QKI associated superenhancers (Q3SE1/2) presented in two Angiocentric Gliomas. (c) MYB promoter activation
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Figure 2.9

Figure 2.9. H3K27ac enhancer profiling of 3’QKI in a human Angiocentric Glioma.
H3K27ac peaks are depicted.
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Figure 2.10

MYB

Figure 2.10. H3K27ac enhancer formation at the MYB promoter in two human MYB-QKI
Angiocentric Gliomas (top tracks) and a BRAF altered Pilocytic Astrocytoma (lower track).
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Figure 2.11
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Figure 2.11. Supplementary figures for MYB-QKI assays (a) MYB promoter activation in
HEK293T and NIH3T3 cells with and without expression of MYB-QKI. (b) Exogenous
expression of MYB-QKI and MYBtr in NIH3T3 cells and mouse neural stem cells via retroviral
transduction. (c) Representative OLIG2 and GFAP immunohistochemical analysis of tumors
from mNSCs overexpressing MYBtr, MYBQKI5, MYB-QKI compared to eGFP controls.
Positive staining for both OLIG2 and GFAP is observed in a subset of tumors cells in tumors
generated from MYBtr or MYBQKI5 overexpression, while tumors formed by MYB-QKI6
overexpression are negative for OLIG2 and have low GFAP expression. Scale bars=50 microns.
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Figure 2.12

Figure 2.12. MYB-QKI and MYBtr are oncogenic. (a) In vitro cell proliferation rates of
mNSCs over-expressing eGFP, MYB-QKI5 (Short) or MYB-QKI6 (Short). Mean of five
independent pools are depicted. Error bars represent SEM. Representative images intracranial
mNSC-MYB-QKI6 tumors. (b) Tumor growth following flank injections of NIH3T3 cells
overexpressing MYB, MYB-QKI5 (Long), MYB-QKI6 (Long) or a vector control. Mean of five
measurements are depicted. Error bars represent SEM. (c) In vitro cell proliferation of mouse
neural stem cells which over-express MYBtr or eGFP controls. Mean of five independent pools is
depicted. Error bars represent SEM. Representative images of intracranial mNSC-MYBtr tumors.
(d) Tumor growth following flank injections of NIH3T3 cells overexpressing MYB, MYBtr or
vector control. Mean of five measurements is depicted. Error bars represent SEM. (e)
Hematoxylin and eosin (H&E) analysis of SCID mouse brain after striatal injections with mNSCs
expressing eGFP, MYBtr, MYBQKI5 or MYBQKI6. Scale bars=2.0mm (top) or 50 microns
(bottom). (f) Kaplan-Meier survival analysis of orthotopic SCID mice injected with mNSCs
overexpressing MYBtr, MYBQKI5, or MYBQKI6 develop tumors with short latency compared
to mNSCs expressing eGFP which never developed tumors, p<0.01.
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Figure 2.13 Oncogenic assays of MYB-QKI expressing cells. (a) Number of colonies of
NIH3T3 cells expressing MYB, MYB-QKI or a vector control in soft agar (Left) and
representative images (right). NIH3T3 cells over-expressing BRAFV600E are shown as a
positive control. Mean of three replicate measurements are shown. Error bars represent SEM. (b)
Table of tumor penetrance from both 3T3 and mNSC models with overall p-value<0.001.
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Figure 2.14
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Values represent mean ± SEM. RNA-sequencing data of Exon 8 of QKI revealed a high number
of duplicate reads and thus is not shown. (b) Cell proliferation of mouse neural stem cells
expressing MYBtr, MYB-QKI5, MYB-QKI6 or eGFP control with suppression of wild-type Qk.
Values represent mean of four independent experiments ± SEM. (c) Expression of signature
within each tumor is the sum of rpkm of each gene in the signature.
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Figure 2.15
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Figure 2.15. QKI knockdown in MNSCs and supplementary assays (a) Suppression of wild
type Qk in mouse NSC expressing MYB-QKI following infection with shQKI vectors (or shLacZ
control). (b) Proliferation of mouse NSC over-expressing eGFP, MYBtr or MYB-QKI with
suppression of wild type Qk over five days in Pool 4 (Values represent mean of 5 replicate
measurements with SEM). Expression of wild type Qk relative to shLacZ control is shown. (c)
shQK signature defined following suppression of wild type Qk in mouse neural stem cells that
over-express MYB-QKI6.
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Figure 2.16

Figure 2.16. The MYB-QKI rearrangement contributes to oncogenesis through at least
three mechanisms. The MYB-QKI rearrangement disrupts both MYB and QKI, resulting in
hemizygous deletion of 3’MYB and 5’ QKI. This results in proximal translocation of H3K27ac
enhancers on 3’QKI towards the MYB promoter, resulting in MYB promoter activation (i). The
MYB-QKI fusion protein that is expressed is oncogenic, functions as a transcription factor, and
exhibits the ability to bind to and activate the MYB promoter, resulting in an auto-regulatory
feedback loop (ii). Hemizygous loss of QKI results in suppression of QKI expression, which
functions as a tumor suppressor gene (iii).
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Figure 2.17. Validation of MYB ChIP-seq. MYB binding to reported MYB target genes in
K562 cells. ChIP-seq enrichment was performed using Abcam 45150.
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Figure 2.18

Figure 2.18. Validation of MYB DNA binding motif in MYB-QKI (a) Top four enriched DNA
binding motifs in MYB ChIP-seq peaks obtained from mNSC over-expressing MYB-QKI. (b)
MYB DNA-binding motifs. (c) Venn diagrams showing overlap of identified MYBQKI peaks
identified (p threshold 1e-6) compared to those reported in Zhao et al and Quintana et al. p values
shown were calcuated by Chi Square with Yates correction. Of 2879 genes identified in our set
20% (Zhao) and 42% (Quintana) were also identified in these studies.
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CHAPTER 3: RAF1 gene fusions in pediatric low-grade gliomas
show differential response to targeted therapeutics based on
dimerization profiles.
Summary
Pediatric low-grade gliomas (PLGGs) are associated with dysregulated MAPK signaling, most
commonly driven by gene fusions involving BRAF. This has led to the initiation of several
clinical trials utilizing RAF and MAPK targeted therapeutics for PLGGs. While the majority of
infratentorial PLGGs harbor BRAF gene fusions, a small number have been recently found to
harbor gene fusions involving another RAF isoform, CRAF/RAF1. In this study, we
unexpectedly found distinct responsiveness of RAF1 fusions to clinically relevant RAF-targeted
therapies. We show that CRAF fusions, QKI-RAF1 and SRGAP3-RAF1 are oncogenic in
multiple cellular contexts through activation of the MAPK and PI3K signaling pathways. While
both BRAF and CRAF fusions resist suppression with first-generation RAF inhibitor
Vemurafenib, only BRAF fusions exhibited growth inhibition and reduced MAPK signaling in
response to second-generation paradox breaking RAF inhibitor PLX8394. We further
demonstrate that unlike BRAF fusions, RAF1 fusions retained robust homo- and heterodimerization in the presence of PLX8394 and disrupting dimerization through point mutations or
with the novel LY3009120 RAF dimer inhibitor significantly reduced the oncogenicity of RAF1
fusions. Intriguingly, using dimerization point mutants of QKI-RAF1, we found that altering the
dimerization domains in N-terminal QKI had a significantly larger effect on oncogenic phenotype
compared to disruption of C-terminal RAF1 dimerization. This suggests a previously
unrecognized role for N-terminal partner protein in mediating dimerization of RAF1 gene fusions
and potential resistance mechanism to paradox breaker RAF inhibitors. Finally, we tested
therapeutic targeting of downstream MAPK pathway in RAF1 fusions using the MEK inhibitor,
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Trametinib and observed partial suppression of tumor growth. Using combinatorial targeting of
both MAPK and PI3K pathway was more successful in suppressing RAF1 fusion induced tumor
growth.

Introduction
As the most common set of brain tumors in children (Kleihues et al., 2002), pediatric low-grade
gliomas (PLGGs) represent a heterogeneous group of tumors with histologies ranging from
pilocytic astrocytomas (WHO grade I) to diffuse fibrillary astrocytomas (WHO grade II). Despite
having good overall prognosis, children with PLGGs often suffer from long-term treatment
related and tumor related complications (Sievert & Fisher, 2009). Mutations involving BRAF,
mostly the KIAA1549-BRAF gene fusion that activates the MAPK pathway, have predominantly
been associated with pilocytic astrocytomas (PAs) (Jacob et al., 2009; Sievert et al., 2009; A. J.
Sievert et al., 2013). However, recent sequencing studies have discovered the occurrence of rare
CRAF (or RAF1) gene mutations, QKI-RAF1 and SRGAP3-RAF1, in PLGGs (D. T. Jones et al.,
2009; J. Zhang et al., 2013). But the prevalence, oncogenic mechanism of action and sensitivity
of the novel RAF1 gene fusions to targeted therapeutics remains unknown.
Whole-genome sequencing studies first detected QKI-RAF1 as an infrequent gene fusion in
pilocytic astrocytomas (J. Zhang et al., 2013) whereas SRGAP3-RAF1 was first reported as a
tandem duplication event that leads to a copy number gain at chromosome 3p25 in a pilocytic
astrocytoma (D. T. Jones et al., 2006; D. T. Jones et al., 2009). While SRGAP3-RAF1 has been
reported to activate the MAPK pathway, no further studies have been conducted on these RAF1
gene fusions to assess response to therapy. Another RAF1 gene fusion, called FYCO1-RAF1, has
also been detected in PLGGs (J. Zhang et al., 2013). These studies add further complexity to the
molecular classification schemes that are currently being developed for PLGGs, as there seems to
be genetic diversity even within the same histologic subtype.
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To study the PLGG-associated RAF1 fusions, QKI-RAF1 and SRGAP3-RAF1, we performed
cellular, molecular, biochemical and in vivo assays to test oncogenic mechanisms activated by
these fusions. Like the BRAF fusions, RAF1 fusions also activate the MAPK signaling pathway
and also a parallel PI3K/mTOR pathway. While first-generation RAF inhibitors such as
vemurafenib do not target PLGGs with BRAF fusion, second-generation PLX8394 inhibits
BRAF fusion’s oncogenicity (A. J. Sievert et al., 2013). Interestingly, we found the RAF1 fusion
to be unresponsive to both first- and second-generation RAF inhibitors. Upon assessing their
dimerization profile, we found dependence of RAF1 fusions on both homodimerization with itself
and heterodimerization with wild type RAF proteins. These protein-protein interactions remained
resistant to second-generation RAF inhibitors but were sensitive to and modified by novel RAF
dimer inhibitor, LY3009120. We also tested the sensitivity of RAF1 fusions to MAPK and
PI3K/mTOR targeted therapeutics as single-agent and combinatorial therapies.

Results
QKI-RAF1 and SRGAP3-RAF1 fusions are oncogenic proteins that activate the MAPK and
PI3K signaling pathways
QKI-RAF1 contains exons 1-3 of the N-terminus of QKI, which belongs to a family of RNA
binding proteins known as the signal transduction and activation of RNA (STAR) proteins (Fig.
3.1a). In this fusion, QKI loses part of its RNA binding domain from the C terminus but retains
an intact homodimerization domain at the N-terminus (Vernet & Artzt, 1997). While QKI is
known to regulate glial development and myelination in the CNS (Friedrich, 1974), loss of QKI
has been detected in glioblastomas (Lawrence et al., 2014; Z. Z. Li et al., 2002; Yin et al., 2009),
angiocentric gliomas (Bandopadhayay et al., 2016), prostate cancer (Y. Zhao et al., 2014), lung
cancer (Zong et al., 2014) and gastric cancer (Bian et al., 2012).
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CRAF/RAF1 is a serine/threonine kinase that was first discovered as the v-raf oncogene in the
transforming mouse sarcoma virus (Rapp et al., 1983; Rapp & Todaro, 1978). Both QKI-RAF1
and SRGAP3-RAF1 fusions have lost the N-terminal non-catalytic domain of RAF1 and the
functional kinase domain is retained (Fig. 3.1a) suggesting auto-activation of the kinase activity.
Several studies have shown that loss of N-terminal domains of RAF1 can lead to oncogenic
activation and tumorigenesis (Cutler et al., 1998; Heidecker et al., 1990; Stanton, Nichols,
Laudano, & Cooper, 1989) but few studies have implicated oncogenic mechanism of RAF1 gene
fusions by focusing on both gene fusion partners.
SRGAP3 is a member of the SLIT-ROBO Rho GTPase-activating protein (srGAP) family and is
involved in several neurodevelopmental processes via regulation of actin cytoskeleton dynamics
(Bacon et al., 2009; Carlson et al., 2011). SRGAP3 possess an N-terminal Fes-CIP4 homology
(FCH) domain and a coiled-coil domain (together called F-BAR domain), a central Rho-GAP
domain and C-terminal SH3 domain (Wong et al., 2001). The SRGAP3-RAF1 gene fusion retains
the FCH domains of SRGAP3 that has been suggested to have dimerization properties (Henne et
al., 2007) whereas the other C-terminal domains are lost. This also suggests a potential role for
the N-terminal fusion protein SRGAP3 to contribute to fusion dimerization, which is a critical
component for activation of RAF1 kinase activity.
While RAF1 gene fusions are rare genetic events in PLGGs, the overall prevalence is not known
due to lack of genomic studies that can enrich for such fusions. However, the occurrence of
different RAF1 gene fusions in adult cancers along with PLGGs (Fig. 3.1b) highlights the
growing importance of studying RAF1 gene fusions and their therapeutic targeting. Majority of
the RAF1 fusions listed in the table have lost the N-terminal auto-inhibitory domains of RAF1
thereby supporting the hypothesis that RAF1 kinase could be constitutively active in RAF1
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fusions, thereby driving tumorigenesis. Therefore, we sought to test the oncogenic potential and
mechanism of action of the PLGG associated RAF1 fusions- SRGAP3-RAF1 and QKI-RAF1.
To study these fusions, we stably expressed SRGAP3-RAF1 and QKI-RAF1 in two different
heterologous cell model systems: NIH3T3 cells and p53-null primary mouse astrocyte cells
(PMAs) (J. Zhang et al., 2013). To assess the oncogenic potential of RAF1 gene fusions, we
performed soft agar assays and measured colony formation. Over-expression of QKI-RAF1 and
SRGAP3-RAF1 in NIH3T3 cells and PMAs was sufficient to drive significant anchorage
independent growth in soft agar compared to vector controls (Fig. 3.1c and 1e, p-value<0.05 to
0.001).
Upon assessing downstream signaling pathways in the stable NIH3T3 cell lines, we found the
mitogen associated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K) signaling
pathway to be aberrantly activated by QKI-RAF1 and SRGAP3-RAF1 as monitored by elevated
phosphorylated MEK land AKT/S6 levels, respectively (Fig. 3.1d). The MAPK signaling
pathway was aberrantly activated by QKI-RAF1 and SRGAP3-RAF1 in PMA cell lines (Fig.
3.1f). The differences in aberrant activation of MAPK and PI3K pathway in the NIH3T3 cell
lines versus the PMA cells is likely due to variation in signaling programs in different cellular
contexts.
To test tumor-forming capacity in vivo, we injected stable NIH3T3 cell lines expressing QKIRAF1 and SRGAP3-RAF1 into flanks of NSG mice. Both RAF1 fusions formed robust flank
xenograft tumors compared to vector controls (Fig. 3.1g, p-value<0.001). Using the stable PMA
cell lines, we performed intra-cranial injections into NSG mice brains. Interestingly, QKI-RAF1
and SRGAP3-RAF1 expressing PMAs but not vector control, caused tumors leading to poor
survival in all mice injected with RAF1 fusion expressing PMAs (Fig. 3.1h, p-value<0.01). These
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findings demonstrate that QKI-RAF1 and SRGAP3-RAF1 are driver oncogenes in PLGGs as they
drive robust oncogenesis in different cell model systems.
First- and second-generation RAF inhibitors do not suppress QKI-RAF1 and SRGAP3RAF1
First generation RAF inhibitors such as vemurafenib (PLX4032) (Bollag et al., 2010) have shown
clinical efficacy and survival benefit in melanomas that harbor the most commonly found BRAF
mutation, BRAF V600E, that changes valine to glutamate at residue 600 in exon 15 (P. B.
Chapman et al., 2011; Flaherty et al., 2010; Sosman et al., 2012). However, we have previously
shown that PLGGs with BRAF fusions such as KIAA1549-BRAF also demonstrate resistance to
PLX4720 (research analog of vemurafenib) via paradoxical activation of the MAPK pathway (A.
J. Sievert et al., 2013) (Fig. 3.2). We also demonstrated that KIAA1549-BRAF was responsive to
a second-generation RAF inhibitor, PLX8394, which is termed as a ‘paradox breaker’ due to
evasion of paradoxical MAPK pathway activation (A. J. Sievert et al., 2013; C. Zhang et al.,
2015). Although several RAF inhibitors are currently being tested in clinical trials for PLGGs,
there are no existing studies examining how the RAF1 gene fusions would respond to these firstand second-generation RAF inhibitors, compared to BRAF fusions.
We tested the response of NIH3T3 and PMA cell models expressing QKI-RAF1 and SRGAP3RAF1 to increasing concentrations of first- and second-generation RAF inhibitors, PLX4720 and
PLX8394, respectively. In NIH3T3 lines expressing QKI-RAF1, both the first- and secondgeneration inhibitors caused paradoxical activation of MAPK pathway as evident by elevated
phospho-MEK and phospho-ERK levels with increasing drug concentrations (Fig. 3.3a).
Interestingly, we observed a partial suppression of phospho-S6 signal at high concentrations of
the drugs despite paradoxical phosphorylation of AKTT308 with PLX8394 (Fig. 3.3a), suggesting
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some downregulation of PI3K pathway. We also observed similar paradoxical activation of
MAPK pathway in stable PMA cell lines with QKI-RAF1 (Fig. 3.3e). However, both RAF
inhibitors failed to suppress QKI-RAF1 driven soft agar colony growth and instead showed
paradoxical increase in oncogenic growth (Fig. 3.3b, f).
SRGAP3-RAF1 expressing NIH3T3 lines showed a similar paradoxical increase in MAPK
pathway with increasing PLX4720 and PLX8394 concentrations (Fig. 3.3c) with some PI3K
pathway suppression. Again, there was no decrease in SRGAP3-RAF1 driven soft agar colony
growth in the presence of the RAF inhibitors in both NIH3T3 cells and PMAs (Fig. 3.3 d, g,
respectively). These findings show a direct correlation of drug-induced paradoxical activation of
the MAPK pathway in RAF1 fusion cells and unresponsiveness to first- and second-generation
RAF inhibitors. Even though the PI3K pathway was affected by high RAF inhibitor
concentrations by some unknown mechanism, lack of suppression of soft agar growth suggests
that it could be secondary to MAPK pathway in driving the RAF1 fusion cells.
RAF1 fusions function as homodimers and heterodimers with B/CRAF that are resistant to
second-generation paradox breakers
The chemical structure of PLX8394 has been shown to prevent RAF dimerization by interacting
with residues on the regulatory spine of RAF kinases (C. Zhang et al., 2015) but our findings
suggest that RAF1 fusions respond differentially compared to wild type proteins. Since RAF
homodimerization and heterodimerization is important for activation of RAF kinase activity
(Rajakulendran, Sahmi, Lefrancois, Sicheri, & Therrien, 2009) and the oncogenic kinase activity
of KIAA1549-BRAF fusion has been attributed to homodimerization (A. J. Sievert et al., 2013),
we hypothesized that the RAF1 gene fusions could be functioning via homodimerization and/or
heterodimerization dependent activation. The presence of dimerization domains in both QKI (Ali
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& Broadhurst, 2013; T. Chen & S. Richard, 1998)/ SRGAP3 (Henne et al., 2007) and RAF1
(Hatzivassiliou et al., 2010; Rajakulendran et al., 2009) suggests that both fusion partners in
RAF1 fusions could be contributing to homodimerization and/or heterodimerization. Therefore,
we characterized how such protein-protein interactions could be responsible for oncogenic
activity and RAF inhibitor resistance in RAF1 gene fusions.
To test the dimerization potential of RAF1 fusions, we assessed the ability of QKI-RAF1 to
interact as homodimers and also heterodimerize with wild type BRAF, CRAF, QKI and truncated
QKI (exons 1-3) by using myc- and flag-tagged constructs. Upon immunoprecipitation (IP) of
QKI-RAF1 with a Myc antibody, we detected QKI-RAF1 protein-protein interactions with QKIRAF1 itself, wild type BRAF, CRAF, QKI and truncated QKI but not the vector control (Fig.
3.4). Similarly, SRGAP3-RAF1 also shows home-dimerization and heterodimerization with wild
type BRAF, CRAF (Fig. 3.5). These results suggest that dimerization may underlie the activation
and functionality of RAF1 fusion kinases.
Previous studies have shown that first-generation RAF inhibitor vemurafenib induces paradoxical
activation of MAPK pathway by binding to one protomer of wild type RAF dimer and transactivating the other uninhibited RAF protomer (Hatzivassiliou et al., 2010). Modifications to
structure of vemurafenib resulted in PLX8394 that has been shown to evade paradoxical
activation in wild type BRAF and BRAFV600E mutant cells (C. Zhang et al., 2015). Since
PLX8394 does not suppress RAF1 fusion mediated oncogenic growth, we next evaluated whether
this unresponsiveness is due to inability of the drug to bind and disrupt RAF1 fusion’s proteinprotein interactions. We found that PLX8394 was unable to disrupt QKI-RAF1 mediated homodimerization and heterodimerization with wild type B/CRAF or QKI (Fig. 3B). This is in contrast
to PLX8394 disrupting the homodimerization of KIAA1549-BRAF fusion (Fig. 3.4c), where we
have previously shown that the paradox breaker (PLX8394) is functional in suppressing
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oncogenicity (A. J. Sievert et al., 2013). This suggests a correlation between dimer inhibition in
the presence of PLX8394 and responsiveness to drug, thereby rationalizing why clinically
relevant RAF inhibitors do not suppress CRAF fusions but BRAF fusions can be suppressed with
paradox breaker drugs.
RAF1 fusions activate oncogenic signaling in a dimerization-dependent manner
QKI-RAF1 and SRGAP3-RAF1 both retain the active RAF1 kinase domain, including specific
residues critical for forming the dimer interface of RAF1 (Bollag et al., 2010; Rajakulendran et
al., 2009). Point mutations in key dimer interface residues of RAF1 (R401H) have been shown to
disrupt RAF1 dimerization with little to no effect on basal kinase activity (Freeman, Ritt, &
Morrison, 2013a, 2013b). We assessed whether mutating the critical dimerization residues of
RAF1 would disrupt the fusion’s dimerization capacity using QKI-RAF1 (denoted as QKIRAF1R401H). In co-IP assays, we observed that QKI-RAF1 homodimerization was unaffected with
QKI-RAF1R401H (Fig. 3.6a) indicating that RAF1 fusion partner was not necessary for
dimerization. QKI-RAF1R401H showed decreased dimerization with wild type BRAF and CRAF
proteins (Fig. 3.6b, c) and also with wild type QKI (Fig. 3.6d) by unknown mechanisms. These
findings with the R401H mutants suggest that while RAF1 dimer interface is critical for
interaction with wild type B/CRAF, it is only partly responsible for QKI-RAF1 mediated
dimerization.
We next assessed the dimerization motif of the N-terminal partner, QKI. The N-terminal QUA1
region of QKI contains dimerization elements and a point mutation E48G in the key dimerization
residue results in disruption of QKI dimers and RNA binding function (Ali & Broadhurst, 2013;
Beuck, Qu, Fagg, Ares, & Williamson, 2012). This mutation (QKIE48G-RAF1) robustly decreased
homodimerization with QKI-RAF1 (Fig. 3.6a) and heterodimerization with CRAF and QKI (Fig.
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3.6 c, d). These data suggest a critical role for the QKI fusion partner in mediating dimerization
and downstream functionality of QKI-RAF1. Even CRAF interaction was affected with QKIE48GRAF1 whereas CRAF interaction is expected to be mediated by RAF1 and not QKI. This hints at
the possibility that QKI-RAF1 forms homodimers followed by CRAF binding to form complex
oligomers but this needs to be tested further. It could be possible that due to loss of QKIE48GRAF1 homo-dimerization, CRAF does not interact with QKIE48G-RAF1 (Fig. 3.6 c).
Next, we tested double point mutants with mutations in dimerization residues of both QKI and
RAF1 (denoted as QKIE48G-RAF1R401H). In co-IP assays, QKIE48G-RAF1R401H double mutant
showed severe loss of interaction with QKI-RAF1, wild type BRAF, CRAF and QKI (Fig. 3.6).
Overall, these results suggest that the N-terminal fusion partner (QKI) primarily mediates RAF1
fusion’s dimerization with some contribution of RAF1 as mutating dimerization residues in both
QKI and RAF1 results in robust loss of all protein-protein dimerizations.
We further tested the effect of QKI, RAF1 and double dimer mutants on oncogenic signaling and
tumorigenic phenotype of QKI-RAF1. We transduced mouse astrocyte cells with various dimer
mutant constructs and tested downstream MAPK signaling. As compared to QKI-RAF1, QKIRAF1R401H showed similar phospho-MEK, phospho-ERK and phospho-S6 levels whereas
QKIE48G-RAF1 and QKIE48G-RAF1R401H had robust reduction in MAPK signaling (Fig. 3.6e).
QKIE48G-RAF1R401H also demonstrated reduction in phospho-S6 beyond the basal level. These
results strongly suggest the importance of QKI fusion partner driving QKI-RAF1 dimerization
and subsequent activation of oncogenic MAPK signaling. When tested in soft agar assays for
tumorigenic potential, QKI-RAF1R401H showed a decrease in colony formation but was not
significantly different from QKI-RAF1 (Fig. 3.6f). In contrast, QKIE48G-RAF1 and QKIE48GRAF1R401H displayed little anchorage-independent growth compared to QKI-RAF1 (Fig. 3.6f, pvalue <0.01), demonstrating that QKI-RAF1 driven soft agar growth is primarily dependent on
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QKI dimerization residues. Hence, disruption of QKI-driven dimerization would be required to
suppress oncogenic properties of QKI-RAF1 expressing PLGGs.
We also evaluated effects of R401H mutation on SRGAP3-RAF1. MAPK signaling was
decreased in mouse astrocyte cells expressing SRGAP3-RAF1R401H as compared to SRGAP3RAF1 but was more than baseline vector control (Fig. 3.5b). In soft agar assays SRGAP3RAF1R401H showed a significant decrease in oncogenic colony formation indicating the role RAF1
dimerization motif in SRGAP3-RAF1 (Fig. 3.5c).
N-terminal fusion partner looses functionality in RAF1 fusions
The loss of RNA binding function of QKI has been associated with increased oncogenicity in
adult glioblastomas (A. J. Chen et al., 2012) and lung cancers (Zong et al., 2014) and decreased
QKI expression has been correlated with occurrence of prostate cancer (Y. Zhao et al., 2014) and
gastric cancer (Bian et al., 2012). Since part of the QKI RNA binding motif is retained in QKIRAF1, we tested whether QKI has lost its RNA binding function in QKI-RAF1 and how that
could correlate with oncogenicity in PLGGs. We performed UV cross-linking experiments where
well-known RNA targets of QKI, myelin basic protein (MBP) and early growth response gene-2
(EGR-2) (Galarneau & Richard, 2005), were radiolabeled and incubated with vector control, full
length QKI and QKI-RAF1. Compared to negative vector control, QKI bound to both RNA
targets but QKI-RAF1 failed to bind either RNA target (Fig. 3.6g, 3.7) thereby indicating that
QKI-RAF1 has lost RNA binding function. We have previously shown that partial loss of QKI
expression in MYB-QKI expressing PLGGs leads to increased oncogenicity (Bandopadhayay et
al., 2016) and such a mechanism could also be possible in QKI-RAF1 expressing tumors. These
results suggest the possible contribution of QKI loss of function in mediating QKI-RAF1
oncogenicity.
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SRGAP3 has also been reported as a tumor suppressor-like gene with low expression in breast
cancer cells (Lahoz & Hall, 2013). Loss of the functional Rho-GTPase domains in SRGAP3RAF1 suggests a loss of function for SRGAP3, similar to QKI in QKI-RAF1. This needs to be
further explored as a common theme for N-terminal fusion partners contributing to RAF1
fusion’s oncogenicity.
RAF1 fusions are sensitive to LY3009120, a RAF dimer inhibitor
Since dimerization is a key component of RAF1 fusion’s oncogenicity, we investigated the effect
of novel dimer inhibitor LY3009120 that has recently shown efficacy in suppressing mutant
BRAF dimers in adult cancers (S. H. Chen et al., 2016; Henry et al., 2015; Peng et al., 2015).
LY3009120 is a pan-RAF inhibitor with potent anti-tumor effects and does not result in
paradoxical activation unlike vemurafenib. In stable NIH3T3 cells, LY3009120 showed potent,
dose-dependent inhibition of both MAPK and PI3K pathways driven by QKI-RAF1 and
SRGAP3-RAF1 (Fig. 3.8a). Even low doses of LY3009120 were successful at suppressing
anchorage independent growth driven by RAF1 fusions in NIH3T3 cells (Fig. 3.8b, pvalue<0.001). Similar suppression of MAPK pathway was observed at high concentrations of
LY3009120 in RAF1 fusion expressing mouse astrocyte cell lines (Fig. 3.8c) whereas PI3K
pathway was not abolished as seen in NIH3T3 cell lines. Nevertheless, LY3009120 potently
suppressed soft agar colony growth of mouse astrocyte cell lines at low doses (Fig. 3.8d)
verifying the specific anti-tumor effects of LY3009120 on RAF1 fusion expressing cell lines.
LY3009120 induces RAF1 fusion homodimerization and heterodimerization with B/CRAF
but prevents QKI heterodimerization
To further evaluate the inhibitory mechanism of LY3009120 in RAF1 fusions, we performed
drug co-IP assays as before. Treatment with 10μM of LY3009120 induced QKI-RAF1
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homodimers and QKI-RAF1/BRAF heterodimers (Fig. 3.8e) with minimal effect on QKIRAF1/CRAF heterodimers. Interestingly, we observed complete disruption of QKI-RAF1/fulllength QKI heterodimerization in the presence of LY3009120 but interaction with N-terminal
truncated QKI is retained (Fig. 3.8e). These results suggest that while LY3009120 induces and
stabilizes QKI-RAF1 homo-dimers and hetero-dimers with other RAF proteins, it suppresses the
RAF1 kinase domains and prevents downstream MAPK/PI3K signaling (Fig. 3.8a, c). However,
LY3009120 disrupts interaction of full length QKI via some unknown mechanism suggesting that
LY3009120 can inhibit QKI dimerization residues in QKI-RAF1, subsequently decreasing QKIRAF1 dimerization and downstream MAPK/PI3K signaling. The unique ability of dimer inhibitor
LY3009120 to suppress RAF1 fusions, where existing RAF inhibitors (PLX4720 and PLX8394)
fail, could be used as a therapeutic option that warrants more testing.
RAF1 fusions are partially suppressed by MAPK pathway inhibitors in vivo
Because of the lack of preclinical efficacy of existing RAF inhibitors in RAF1 fusions, we next
tested effects of clinically available MAPK pathway inhibitors, AZD6244 and trametinib
(GSK1120212), as single agent therapies against RAF1 fusions. NIH3T3 cell lines overexpressing QKI-RAF1 and SRGAP3-RAF1 showed a dose dependent decrease in phospho-ERK
levels with AZD6244 indicating on-target inhibition of MEK1/2 (Fig. 3.9 a, d respectively, left
panels). In soft agar assays, AZD6244 showed robust growth inhibition against NIH3T3 cells
expressing QKI-RAF1 and to a lower extent for SRGAP3-RAF1 (Fig. 3.9 b, e respectively, top
panel, p-value<0.01, 0.1). We also evaluated a more potent MEK inhibitor and FDA approved
MEK inhibitor, Trametinib. We observed robust decrease in phospho-ERK levels with trametinib
treatment in NIH3T3 cells expressing QKI-RAF1 and SRGAP3-RAF1 (Fig. 3.9 a, d respectively,
middle panels) and also in mouse astrocyte cell lines stably transduced with QKI-RAF1 and
SRGAP3-RAF1 (Fig. 3.9 a, d respectively, right panels). Even low doses of trametinib were
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successful in inhibiting anchorage independent growth driven by QKI-RAF1 and SRGAP3-RAF1
in NIH3T3 cells (Fig. 3.9 b, e respectively, top panels, p-value<0.01) and in mouse astrocyte cell
lines (Fig. 3.9 b, e respectively, bottom panels, p-value<0.01). These in vitro studies suggest that
trametinib can suppress MAPK signaling and in vitro colony formation driven by RAF1 fusions;
hence we tested this mono-therapy in vivo.
We used stable NIH3T3 cell lines expressing RAF1 fusions to form flank xenograft tumors in
immuno-compromised mice and treated mice daily with trametinib at 1 mg/kg. Despite
significant activity in vitro, Trametinib mono-therapy only partially suppressed QKI-RAF1 and
SRGAP3-RAF1 tumor growth (Fig. 3.9 c, d, respectively). The recurrence of tumors in the
setting of continued trametinib treatment suggests that alternate resistance pathways were
activated by RAF1 fusions in vivo.
Combinatorial targeting of MAPK and PI3K/mTOR pathways is more potent in
suppressing RAF1 fusions than single agent therapies
Because we observed PI3K/mTOR pathway activation in RAF1 fusion expressing cell lines, we
sought to test combination therapy targeting both MAPK and PI3K pathways for RAF1 fusions
using MEK inhibitor trametinib and PI3K/mTOR pathway inhibitor RAD001 (Everolimus).
NIH3T3 and mouse astrocyte cells expressing QKI-RAF1 (Fig. 3.10a, left and right panel
respectively) revealed decrease in phospho-ERK and phospho-S6 at very low doses of trametinib
and 10μM RAD001 indicating targeting of oncogenic signaling. Similar decrease in MAPK and
PI3K/mTOR signaling was observed in SRGAP3-RAF1 expressing NIH3T3 and mouse astrocyte
cells (Fig. 3.10c, left and right panel respectively).
To test the effect of combinatorial treatment on oncogenic growth inhibition in vitro, we
performed soft agar assays with RAF1 fusion expressing NIH3T3 and mouse astrocyte cells. In
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both cell model systems, combinatorial targeting was successful at inhibiting anchorage
independent growth mediated by RAF1 fusions (Fig. 3.10 b, d).
We then evaluated sensitivity to combinatorial therapy in in vivo models with NIH3T3 flank
xenografts. As seen in Figure 3.10 e, mice with QKI-RAF1 xenografts treated with single-agent
RAD001 or trametinib show initial tumor suppression but tumor eventually resurges. QKI-RAF1
xenograft mice treated with trametinib and RAD001 at 1mg/kg and 10mg/kg, respectively show
prolonged suppression of tumor growth (Fig. 3.10e). We observed similar responsiveness in
SRGAP3-RAF1 expressing NIH3T3 flank xenografts, with single-agent therapy against MAPK
or PI3K/mTOR leading to only partial tumor suppression and combinatorial targeting causing
more prominent, prolonged tumor regression (Fig. 3.10f). These in vivo results strongly suggest
the significance of using combinatorial therapy with trametinib and RAD001 for RAF1 fusion
expressing PLGGs as targeting both signaling pathways would be essential for effective targeted
therapy.

Discussion
In this study, we describe the oncogenic mechanism of action and therapeutic sensitivity of
PLGG associated RAF1 gene fusions. To our knowledge, this is the first report to distinguish
between BRAF and CRAF/RAF1 gene fusions, both found in the grade I PLGG, pilocytic
astrocytomas (PAs) (J. Zhang et al., 2013). While BRAF fusions result in paradoxical activation
with vemurafenib, a first generation RAF inhibitor, second generation PLX8394 suppresses
BRAF fusion driven oncogenesis. Interestingly, RAF1 fusions are not suppressed by either
vemurafenib or PLX8394 but are responsive to novel dimer inhibitor LY3009120 or
combinatorial targeting with MAPK and PI3K/mTOR pathway inhibitors, highlighting important
clinical implications. We also report a critical role of the N-terminal fusion partner, QKI in
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mediating QKI-RAF1 fusion’s oncogenic nature and resistance to existing RAF inhibitors, a
finding that might be relevant to pan-cancer RAF1 gene fusions.
The BRAFV600E mutation is found in 6-10% of PAs with other subtypes displaying higher
incidences (Olow et al., 2016) whereas the KIAA1549-BRAF fusion has been reported in majority
of PAs, and novel BRAF mutations have also being discovered by deep sequencing (J. Zhang et
al., 2013). The overall frequency of BRAF mutations is much higher in PAs with a small fraction
of patients containing RAF1 gene fusions, however their overall prevalence remains unknown.
Since both RAF1 fusions and BRAF fusions occur in the same PLGG sub-type (J. Zhang et al.,
2013), patients with a clinical diagnosis of PAs might not have the same molecular diagnosis.
This necessitates development of molecular stratification schemes for PLGGs as patients with
similar histological diagnosis might have different molecular drivers.
We found QKI-RAF1 and SRGAP3-RAF1 to be oncogenic proteins in different cellular contexts
that drive robust in vivo flank xenograft and intra-cranial tumor growth. Relevant patient-derived
models are extremely rare for PLGGs, with the few reported cell lines not expressing RAF1
fusions (Bax et al., 2009; Olow et al., 2016). In our model systems, RAF1 fusions were found to
aberrantly activate both the MAPK and PI3K/mTOR pathways. Despite similar downstream
signaling to BRAF fusions, RAF1 fusions were found to function differentially and exist as RAF
inhibitor resistant homodimers and heterodimers with B/CRAF. This is in contrast to KIAA1549BRAF fusion that exists solely as homodimers (A. J. Sievert et al., 2013) that we found to be
disrupted in response to PLX8394. Alternatively, BRAFV600E exists as monomers that are
targetable by both vemurafenib and PLX8394 (Freeman et al., 2013a; Poulikakos et al., 2011; C.
Zhang et al., 2015). Differences in response to RAF inhibitor therapy and BRAF mutational
status has been reported previously but our findings suggest unique differences between BRAF
and CRAF fusions based on dimerization status, primarily mediated by the non-kinase fusion
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partner in RAF1 fusions. These mechanistic findings have important implications when assessing
therapeutic options for patients with RAF1 fusions, as clinically available RAF inhibitors would
be unsuccessful in disrupting oncogenic dimers of RAF1 fusions, rendering patients resistant to
therapy.
LY3009120 is a novel RAF dimer inhibitor drug that has shown promise in inhibiting models
with various NRAS, KRAS and BRAF mutations (S. H. Chen et al., 2016; Peng et al., 2015). We
demonstrate ability of LY3009120 to disrupt QKI mediated interaction between QKI-RAF1
fusions as well as stabilize inactive homodimers and heterodimers with B/CRAF. This strongly
supports our hypothesis that RAF inhibitor can be effective against RAF1 fusions if would it
targets dimerization mediated by both fusion partners. Due to distinct binding properties of
LY3009120, its clinical use could extend from BRAF mutant cancers to RAF1 fusion expressing
cancers but this would require further in vivo testing.
The RAS/RAF/MEK signaling cascade is altered in a variety of cancers leading to the successful
development of potent targeted inhibitors for the downstream kinases, MEK1/2, such as
Selumetinib (AZD6244) and Trametinib (GSK1120212) (Gilmartin et al., 2011; Henne et al.,
2007; Yamaguchi, Kakefuda, Tajima, Sowa, & Sakai, 2011). While AZD6244 monotherapy has
been tested against adult cancers (Catalanotti et al., 2013) and is also currently in clinical trial for
PLGGs (ClinicalTrials.gov Identifier: NCT01089101), we have shown limited response to
AZD6244 monotherapy in RAF1 fusion expressing cell models. This led us to focus efforts on
the more potent Trametinib that has also been approved for advanced, refractory melanomas
(Flaherty et al., 2012). In BRAF mutant cancers, monotherapy with MEK inhibitor is more potent
than RAF inhibitors but multi-agent therapy combining MEKin with either Vemurafenib or
mTOR inhibitor (Everolimus) has shown the most promising pre-clinical results (Olow et al.,
2016). In our study, Trametinib monotherapy showed partial suppression of RAF1 fusion driven
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tumor growth, highlighting the importance of the parallel PI3K/mTOR pathway in RAF1 fusion
driven PLGGs. Therefore, we tested combinatorial therapy using MEKin Trametinib and
mTORin Everolimus (RAD001) and found combinatorial treatment to be most successful at
prolonged suppression of QKI-RAF1 and SRGAP3-RAF1 driven tumors. This provides a strong
rationale for clinical use of dual therapy for PLGGs with RAF1 fusion. Safety and tolerability of
combining MEK- and mTOR-inhibitors is currently being in adult, advanced cancers
(ClinicalTrials.gov Identifier: NCT01347866) with pediatric testing in the future (Olow et al.,
2016).
Most studies on kinase gene fusions have focused on the downstream effects of truncated,
activated kinases, whereas our study depicts a novel oncogenic role for the non-kinase fusion
partner. We found that stable dimerization of QKI-RAF1 is mediated by QKI and is essential for
resistance to RAF inhibitor therapy. This adds to the growing list oncogenic roles being attributed
to QKI by recent studies including loss of expression/function and altered regulation of target
RNAs (Abedalthagafi et al., 2015; Bandopadhayay et al., 2016; Conn et al., 2015; DananGotthold et al., 2015) and its growing importance in regulating brain tumors. However, the role of
N-terminal fusion partner might be gene-specific, as the ESRP1-RAF1 fusion exists as a
constitutive dimer where dimerization is mediated by RAF1 and R401H mutation causes loss of
MAPK signaling (Palanisamy et al., 2010; Yao et al., 2015).
The distinct sub-types of pediatric low-grade gliomas are beginning to be associated with specific
mutations such as the association of MYB-QKI with angiocentric gliomas and KIAA1549-BRAF
fusions with pilocytic astrocytomas but this study adds another layer of complexity with same
subtype displaying different mutations and distinct therapeutic responses. We highlight the
importance of molecular classification of PLGGs in assisting targeted therapeutic approaches.
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Materials and Methods
Cell Culture: NIH3T3 and HEK 293 cells were obtained from ATCC and maintained in 1X
DMEM media containing 10% DBS and 10% FBS respectively. We obtained Tp53-null earlypassage primary mouse astrocytes (PMAs) from Suzi Baker’s group at St. Jude Children’s
Hospital, and these cells were maintained in DMEM- F12 media supplemented with 10% FBS
and EGF. Cell lines were not re-authenticated and were routinely tested (at least every three
months) for mycoplasma infection.
Vector Construction and Generation of Stable Cell Lines: SRGAP3-RAF1 and QKI-RAF1
constructs were synthesized as Gateway compatible entry clones. Full length RAF1, QKI and
SRGAP3 plasmids were purchased as gateway entry clones from PlasmID/DF/HCC DNA
Resource Core. Sub-cloning was done to integrate SRGAP3-RAF1, QKI-RAF1, full-length QKI,
RAF and SRGAP3 constructs into a Gateway-compatible N-MYC-tagged pMXs-Puro Retroviral
Vector (Cell Biolabs). Empty MYC-tagged retroviral construct was used as control. Retrovirus
was generated using Platinum-E retroviral packaging cells (Cell BioLabs) as per manufacturer
protocols. NIH3T3 cells and early-passage PMAs were transduced with retroviral media for 6
hours and infected cells were selected with puromycin 48 hours post infection. Stable expression
of MYC-tagged proteins was confirmed via western blot analysis (anti-MYC HRP 1:5000;
Invitrogen). For protein-protein interaction assays, we also cloned the above-mentioned
constructs into Gateway destination vectors with either an N-terminal MYC tag or N-terminal
FLAG tag (Invitrogen).
Dimerization mutants of QKI-RAF1 were generated by PCR-based site-directed mutagenesis of
MYC- and FLAG-tagged constructs described above. RAFR401H dimerization mutants (Freeman et
al.,

2013a,

2013b)

in

QKI-RAF1

were

generated

using

primers:

Forward

CGCAAAACACACCATGTGAACA and Reverse CAGAACAGCCACCTCATTCCT. QKIE48G
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dimerization

mutants

in

QKI-RAF1

were

generated

using

primers:

Forward

CTGGACGAAGGAATTAGCAGAG and Reverse CAGCCGCTCGAGGTGGTT. QKIE48G
dimerization mutants (T Chen & S Richard, 1998) in QKI-RAF1 were generated using primers:
Forward CTGGACGAAGGAATTAGCAGAG and Reverse CAGCCGCTCGAGGTGGTT.
Cellular kinase drug assays: For pathway suppression experiments using RAF inhibitors,
PLX4720, a first-generation RAF inhibitor, or PLX8394/PB-3, a second-generation paradoxbreaking RAF inhibitor (Plexxikon) or LY3009120, a pan-RAF dimer inhibitor (Eli Lilly; drug
purchased from Selleck Chemicals) were used at indicated concentrations. The MEK inhibitor,
GSK1120212 was provided by GlaxoSmithKline, and AZD6244 (Astra Zeneca) was purchased
from Selleck Chemicals. These drugs were used alone or in combination with RAD001 (mTOR
inhibitor). All drug aliquots were dissolved in DMSO and stored at −20 °C. Cells were plated at
1x106 cells/ml in six-well dishes with serum-containing media. Before drug treatment, cells were
serum starved. Thereafter, cells were exposed to indicated drug concentrations for indicated time
periods.
Western Blot Analysis: Stable NIH 3T3 cells and stable PMA cell lines used in drug assays were
lysed in 1X RIPA (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1%
Nonidet P-40) containing protease and phosphatase inhibitor cocktail (Thermo Fisher).
Supernatant from centrifuged lysates were normalized for protein concentration using a Pierce
660nm protein assay and run on NuPAGE precast gels (4–12% Bis-Tris; Life Technologies). For
MAPK pathway analysis, pMEK, MEK, pERK, ERK antibodies from Cell Signaling were used at
1:1000 dilutions in BSA. To analyze PI3K/mTOR pathway, pAKT Ser473, pAKT Thr308, AKT,
pS6, S6 antibodies from Cell Signaling were used.
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Soft-Agar Cellular Transformation Assays and quantification: Anchorage-independent
growth of SRGAP3-RAF1 and QKI-RAF1 expressing stable NIH 3T3 cells and PMAs was
assessed as previously described (Bandopadhayay et al., 2016; Angela J Sievert et al., 2013).
Images were analyzed using ImageJ and colonies with area greater than 500 pixels quantified.
Co-immunoprecipitation Assays: Interactions of SRGAP3-RAF1 and QKI-RAF1 with itself,
wild-type BRAF, CRAF, QKI or SRGAP3 were assessed via co-transfections of MYC- and
FLAG-tagged constructs into HEK 293 cells using Lipofectamine 2000. Anti-MYC tag antibody
coated magnetic beads (MBL) were used to immunoprecipitate the transfected proteins from cell
lysates in 1X RIPA at 4 °C over-night. Beads were washed 3 times for 15 minutes each at 4 °C to
remove non-specific interactions, followed by a final 1xPBS wash. Proteins were eluted off beads
using 2xLDS and heating at 70°C for 10 minutes and used for in western blot analysis. AntiMYC antibody (Invitrogen, 1:5000) and anti-FLAG antibody (Thermo Fisher, 1:10,000) were
used to assess co-immunoprecipitation.
Animal studies: The Children’s Hospital of Philadelphia Institutional Animal Care and Use
Committee approved all animal protocols. Homozygous NSG strain immuno-deficient mice were
bred in our animal facility and housed under aseptic conditions. Mice were 6-10 weeks of age,
with equal representation of male and female mice.
Mouse flank xenograft studies with NIH3T3 Stable Cell Lines: To assess in vivo tumor growth,
NIH3T3 cell lines were injected subcutaneously into the flanks of NSG mice (10 mice for each
cell line, per drug condition) and tumor growth was measured. The GSK1120212 and RAD001
combinatorial drug study was performed in a xenograft mouse model by pre-treating with daily
oral gavage (1 mg/kg/dose of GSK1120212 and 10mg/kg of RAD001) for one week prior to
injecting cell lines subcutaneously into the flanks of NSG mice. Tumor growth was measured
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daily while on drug treatment. Ellipsoid tumor volume was calculated using the formula: volume
= 1/2(length × width2).
Intracranial mouse injections: 1x106 PMAs expressing SRGAP3-RAF1, QKI-RAF1 and vector
control were resuspended in Matrigel basement matrix (BD Sciences) and 2 microliter was
injected stereo-tactically into the right striatum of immuno-compromised NSG mice (5 mice
each). Animals were monitored and sacrificed at the onset of neurological symptoms, QKI-RAF1
at day 39 post-injection and SRGAP3-RAF1 at day 42 post-injection. Brains were isolated post
intra-cardiac perfusion with 4% paraformaldehyde solution and stored in 4% paraformaldehyde
solution in 1X PBS at 4°C over-night, and subjected to routine histological analysis.
UV cross-linking and co-immunoprecipitation assays: To assess the RNA binding capacity of
QKI in QKI-RAF1, known RNA targets of QKI were used- myelin basic protein (MBP) and
early growth Response 2 (EGR-2) (Galarneau & Richard, 2005). In vitro transcription of P32
radiolabeled RNA probes (MBP and EGR-2) and UV cross-linking with QKI or QKI-RAF1
expressing HEK293 lysates was done as described previously (Lynch & Maniatis, 1996;
Rothrock, House, & Lynch, 2005). Cross-linked protein-RNA conjugates were immuoprecipitated using anti-Myc tagged beads and separated on an SDS-PAGE gel.
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Tables and Figures
Figure 3.1

Figure 3.1. QKI-RAF1 and SRGAP3-RAF1 are oncogenic via activation of MAPK and PI3K
pathways. (a) Structure of RAF1 fusions in PLGGs. In QKI-RAF1, exons 1-3 of QKI contain
QUA1 dimerization domain and a truncated K- homology domain (KH-Tr), and exons 8-17 of
RAF1 retain the protein kinase domain. In SRGAP3-RAF1, exons 1-10 of SRGAP3 contain the
Fes/CIP4-Homology (FCH) domain or also called the F-BAR homodimerization domain and,
RAF1 exons 9-17 encode the RAF1 kinase domain. (b) Table showing different RAF1 fusions
present in various adult cancers and pediatric cancer. (c) Soft agar assay using NIH3T3 cell lines
stabling expressing RAF1 fusions. Mean of three measurements is depicted. Error bars represent
SEM. (d) Western blot analysis of MAPK and PI3K pathway in stable NIH3T3 cell lines under
serum starvation. (e) Soft agar assay using p53-null mouse astrocyte cells (PMAs) stabling
expressing RAF1 fusions. Mean of five measurements is depicted. Error bars represent SEM. (f)
Western blot analysis of MAPK and PI3K pathway in stable PMA cell lines under serum
starvation. (g) Flank xenograft tumor measurements with stable NIH3T3 cell lines expressing
RAF1 fusions. Mean of ten measurements is depicted. Error bars represent SEM. (h) KaplanMeier survival plot of NSG mice orthotopically injected with PMAs overexpressing RAF1
fusions develop tumors with short latency compared to PMAs expressing vector control which
never developed tumors, n=5, p<0.01. p-value * <0.05, ** <0.01, *** <0.001.
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Figure 3.2
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Figure 3.2. Effect of RAF inhibitors on KIAA1549-BRAF signaling. Western blots showing
paradoxical activation of PLX4720 on growth pathways regulated by KIAA1549-BRAF
expressing NIH 3T3 cells, PLX8394 can suppress KIAA1549-BRAF signaling.
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Figure 3.3
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Figure 3.3. Existing RAF inhibitors do not suppress CRAF fusion driven signaling
pathways and oncogenic phenotype. Current RAF inhibitors, PLX8394 and PLX4720, have
minimal effect of on (a) growth pathways and (b) soft agar growth regulated by QKI-RAF1
expressed in NIH 3T3 cells. Similar unresponsiveness seen on (c) growth pathway and (d) soft
agars driven by SRGAP3-RAF in NIH 3T3 cells. (e) p53-/- mouse astrocyte cell lines (PMAs)
with QKI-RAF1 and SRGAP3-RAF1 are unresponsive to current RAF inhibitors. Soft agar
growth of PMAs expressing (f) QKI-RAF1 and (g) SRGAP3-RAF1
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Figure 3.4
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Figure 3.4. Homo- and hetero-dimerization is required to drive CRAF fusion driven
gliomagenesis. (a) Co-immunoprecipitation assays show QKI-RAF1 homo-dimerization with
itself, and hetero-dimerization with wild type BRAF, CRAF and QKI in HEK 293t cells. (b)
Presence of ‘paradox breaker’ RAF inhibitor, PLX8394, does not affect QKI-RAF1 dimerization
in co-immunoprecipitation assays in HEK 293t cells. (c) KIAA1549-BRAF homo-dimerization is
suppressed by PLX8394.
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Figure 3.5. SRGAP3-RAF1 mediated dimerization and oncogenicity is partly mediated
by RAF1. (a) SRGAP3-RAF1 homo-dimerizes with itself, and hetero-dimerizes with wild type
BRAF and CRAF. (b) Single dimerization mutants of SRGAP3-RAF1 (RAF1R401H) expressed in
PMAs show reduction in MAPK pathway. (c) Soft agar assays with SRGAP3- RAF1R401H shows
decrease in oncogenicity.
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Figure 3.6
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Figure 3.6. RAF1 fusions activate oncogenic signaling in a dimerization-dependent
manner. Co-IP assays using single dimerization mutants of QKI (QKI E48G-RAF1) and RAF1
(QKI-RAF1R401H) and double dimerization mutants (QKI E48G -RAF1R401H) of QKI-RAF1 against
(a) QKI-RAF1, (b) BRAF, (c) CRAF/RAF-1 and (d) QKI. PMAs expressing QKI-RAF1 mutants
were assessed for (e) MAPK and PI3K pathway signaling and (f) soft agar growth. (g) UV
crosslinking assay with wild type QKI and QKI-RAF1 assessing RNA binding to probes, MBP
and EGR-2.
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Figure 3.8
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Figure 3.8. Novel RAF dimer inhibitor LY3009120 stabilizes and inactivates CRAF fusion
dimers. Western blot showing suppression of QKI-RAF1 and SRGAP3-RAF1 mediated growth
pathways in (a) NIH 3T3 cells and (c) PMAs. Soft agar assays showing robust response to
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Figure 3.9
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Figure 3.9. MEK inhibitors, AZD6244 and GSK1120212, partially suppress QKI-RAF1
mediated tumor growth. (a) Westerns showing effect of MEK inhibitors on growth pathways
by QKI-RAF1 in NIH 3T3 cells. (b) MEK inhibitors partially suppress QKI-RAF1 driven soft
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SRGAP3-RAF1 driven soft agar growth and mouse flank xenografts.
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Figure 3.10

Figure 3.10. Combinatorial targeting of MAPK and PI3K pathway (MEK inhibitors+
mTOR inhibitors) suppresses CRAF fusion driven tumor growth. (a) Westerns showing effect of
MEK+ mTOR inhibitors on growth pathways by QKI-RAF1 and SRGAP3-RAF1 in NIH 3T3
cells. (b) Combination of MEK + mTOR inhibitors robustly suppress CRAF fusion driven soft
agar growth in NIH 3T3 cells. (c) CRAF fusion driven mouse flank xenografts are suppressed by
combinatorial targeting of MAPK and PI3K pathways.
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CHAPTER 4: Discussion
Takes two to tango: QKI gene fusions define novel oncogenic mechanisms
driven by both fusion partners
Rapid advances in deep sequencing technologies and fusion-detection platforms over the past few
years have raised the total number of pan-cancer gene fusions to be around 10,000 (Latysheva &
Babu, 2016; Mertens, Johansson, Fioretos, & Mitelman, 2015). The prevalence of gene fusions
varies widely across adult cancers with the overall frequency of gene fusion being lower than
occurrence of somatic mutations (Lawrence et al., 2013). But for pediatric brain tumors,
especially low-grade gliomas, recent studies suggest that genes fusions are the predominant
pathognomonic events that mediate disease occurrence and progression. Historically, gene
fusions have mostly been characterized to involve kinases and transcriptional control genes
(Mitelman, Johansson, & Mertens, 2004) that exert oncogenesis via constitutive activation of
kinases/signaling pathways or association of a proto-oncogene with a strong promoter,
respectively. In contrast to these mutually exclusive mechanisms, our studies shed light on novel,
collaborative processes that gene fusions utilize to drive pediatric brain tumors. Our findings
show the importance of RNA binding protein QKI as a functional gene fusion partner,
highlighting an important, understudied role for the non-kinase/non-TF related fusion proteins.
Furthermore, we highlight how the combination of specific fusion partners in a gene fusion can
affect not just the pathogenesis and tumor sub-type but also response to targeted therapy.

MYB-QKI: Synergism of a proto-oncogene and a tumor suppressor
MYB-QKI is an archetypal example of a gene fusion that is characteristic of a tumor sub-type and
can be used for diagnostic and molecular subtyping purposes. Our in vitro and in vivo studies
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show that MYB-QKI is a driver mutation in angiocentric gliomas and mediates gliomagenesis via
multiple mechanisms (Fig. 4.1). Truncations in MYB result in constitutively active transcriptional
activity of MYB-QKI, as shown in figure 2.5. Chromosomal rearrangement at 6q results in juxtapositioning of MYB and QKI, causing association of QKI-related enhancers with MYB promoters
leading to MYB-QKI expression.

Interestingly, MYB-QKI is capable of driving its own

expression leading to a unique positive feedback loop. This finding represents a novel mechanism
utilized by an oncogenic gene fusion and also provides a possible opportunity for epigenetictargeted therapies that could possibly block expression of MYB-QKI. Due to lack of patient
derived lines/models, we could not directly assess if there are any other mechanisms driving the
MYB promoter, especially since it is inactive in most brain regions.
In addition to activating the MYB transcriptional axis, MYB-QKI also involves the putative tumor
suppressor gene QKI. Our findings suggest a strong additive effect due to QKI loss of
heterozygosity and oncogenic MYB activation in neural stem cells. To our knowledge, this is the
first demonstration that a proto-oncogene and a tumor suppressor collaborate in a gene fusion
setting to enhance oncogenesis. From a therapeutic standpoint, these findings suggest that it
might be insufficient to target only of the fusion partners to get complete efficacy. While no
approved therapies exist for LOH mutations, epigenetic therapies are emerging as described
below, and might be useful to target aberrant enhancer driven MYB-QKI expression.
Overall these findings have broad implications for distinguishing angiocentric gliomas accurately
from other PLGG sub-types using deep sequencing, RT-PCR or FISH techniques. Other than
diagnostic benefits, novel targeted therapies can also be designed against MYB-QKI expressing
AGs, either targeting epigenetic mechanisms mediating fusion expression or target downstream
pathways driven by MYB-QKI. Furthermore, MYB-QKI can also be used to assess residual
tumor post-surgery, given tumors express the fusion protein homogenously. Future aims of this
101

project would be to assess therapeutic agents against MYB-QKI, such as JQ1 that is an inhibitor
of bromodomain-containing protein BRD4 (Filippakopoulos et al., 2010). This is because BRD4
remains bound to transcriptional start sites of genes (at acetyl-lysine residues) of many genes and
is also a critical mediator of transcriptional elongation (Yang, 2005) and it has shown therapeutic
efficacy in castration-resistant prostrate cancer (Asangani et al., 2014). BRD4 inhibition has also
shown efficacy in suppressing another MYB rearrangement (MYB-NF1b) expressing tumor called
adenoid cystic carcinoma (ACC) (Y. Drier et al., 2016). JQ1 could prevent MYB-QKI driven
oncogenic transcriptional program by disrupting the MYB promoter-enhancer loop but this
hypothesis needs to be tested.

QKI-RAF1: Dimerization and activation of kinase mediated by non-kinase partner
The CRAF fusion, QKI-RAF1, demonstrates another aspect of how QKI can contribute to gene
fusion biology. Since QKI-RAF1 retains the N-terminal portion of QKI (as compared to C
terminus in MYB-QKI), QKI homo-dimerization domain is retained along with portion of the
RBD. This suggested a different mechanism of action for QKI in QKI-RAF1 as opposed to QKI
LOH and associated loss of tumor suppressor function that we see in MYB-QKI. While loosing
it’s RNA binding properties in QKI-RAF1 (Fig. 3.6g), QKI supports the oncogenic kinase
activity of RAF1 via QKI-RAF1 dimerization. We have shown that QKI-mediated dimerization is
key to maintaining stable QKI-RAF1 homo-dimers and subsequent transformation (Fig. 3.6).
Future work in this project will assess the cooperativity of QKI loss of functions and QKI-RAF1
oncogenicity, as we have shown in MYB-QKI tumors.
RAF1/CRAF has lower basal kinase activity compared to BRAF and requires additional
phosphorylation/dephosphorylation steps for activation (Dhillon, Meikle, Yazici, Eulitz, & Kolch,
2002; J. Hu et al., 2013). RAF activation requires phosphorylation at 2 key positions: the Cterminal activation loop (AL) and the N-terminal acidic NtA) motif (Diaz et al., 1997; Mason et
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al., 1999). BRAF has acidic residues in the NtA along with constitutively phosphorylated serines
(SSDD), leaving BRAF in a partially activated state (Mason et al., 1999). RAF1 lacks such
phosphorylation and needs membrane recruitment and dimerization with BRAF to be activated (J.
Hu et al., 2013). RAF1 truncations and QKI mediated dimerization might be helping to bypass
some of these activation steps. This hypothesis needs to be tested further.
Lastly, our findings highlight the evolving role of CRAF in cancer, in contrast to BRAF being
considered the RAF protein of choice for oncogenic mutations. Even though BRAF is one of the
most frequently mutated genes in cancer and is a major focus of targeted therapeutics, this study
strongly suggests the need to delineate the rare CRAF mutations from BRAF mutations as there
could be driving distinct molecular mechanisms to activate the MAPK pathway. While
vemurafenib (PLX4720) doesn’t suppress either BRAF or CRAF fusions in PLGGs, PLX8394
can target only BRAF fusions but not CRAF fusions (Fig. 3.3). Since both BRAF and CRAF
fusions occur in pilocytic astrocytomas, our findings point out a key therapeutic distinction with
differential response to therapy within the same tumor sub-type. While combinatorial targeting
with a MEK and mTOR inhibitor might be necessary/sufficient for targeting CRAF fusions, it is
also essential to test upstream RAF targeting options due to evolving resistance mechanisms with
MAPK targeting (Waanders et al., manuscript under revision with Clinical Cancer Research).
Overall, QKI-RAF1 is the first RAF fusion in PLGGs where the N-terminal non-kinase partner
has been shown to be involved in pathogenesis and therapeutic resistance making QKI-RAF1 a
distinct molecular and therapeutic target (Figure 4.2).

All about that grade: Molecular stratification of PLGG patients
Current clinical practice utilizes the WHO classification as the standard of care for PLGGs
diagnosis, treatment and management (Bergthold et al., 2014) but there is growing consensus that
histopathological classification is not sufficient to discern between heterogeneous tumor subtypes
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(Louis et al., 2014). Lack of accurate diagnosis might occur due to significant overlap in
histologic and clinical features, scare tumor tissue availability, inter-physician variability and
intra-tumoral heterogeneity (Bergthold et al., 2014). Furthermore, our pre-clinical study suggests
that histological grade I tumor, PA, would respond differentially to RAF targeted therapy based
on its mutational profile. Hence, a paradigm shift is impending to integrate traditional
histopathological PLGG classification with emerging molecular and genomic data, as shown in
figure 1.4.
Multiple large-scale sequencing studies have uncovered immense molecular complexity within
PLGGs. To address this, further work needs to be done to develop comprehensive mutational
profiles that correlate with histological tumor grades. Furthermore, our study shows that even
within the same tumor type, distinct molecular entities could exist, requiring even further tumor
sub-typing. Lastly, application in the clinic would require augmenting current diagnostics with
deep sequencing technologies so each patient’s tumor can be sequenced and driving mutations
identified, thereby leading to better clinical outcomes and patient management.

Rolling in the deep-sequencing: Personalized medicine for PLGG patients
Despite good overall survival, long-term PLGG survivors suffer from significant morbidities,
especially when complete surgical resection is difficult due to tumor location, such as in the optic
pathway, hypothalamus, diencephalon, and brainstem. Therefore, development of novel,
mutation-specific therapies is essential to deliver less toxic treatments to the developing nervous
system of young PLGG patients.
Based on the findings from our study and others, it will become imperative to use deep
sequencing techniques to first assess the mutational status of PLGG patients before assigning
therapy. Future work on evaluating the molecular mechanisms of other PLLG-associated gene
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fusions/mutations will add to the growing body of work for devising mutation-specific targeted
therapies. Current clinical trials are assessing RAF inhibitors (Dabrafenib, NCT01677741), MEK
inhibitors (MEK162, NCT02285439; trametinib, NCT02124772 and selumetinib, NCT01089101)
and mTOR inhibitor (Everolimus, NCT01734512) against children with low-grade gliomas.
However, future clinical trials should incorporate genomic sequencing to identify patient-specific
mutations to decide trial eligibility and have maximal efficacy.
PLGG treatment has evolved from radiation therapy once being the standard-of care to surgery
and/or chemotherapy being the first line of therapy currently (Bergthold et al., 2014). Radiation
therapy might still be used in non-surgical, chemotherapy refractory tumors but it can lead to
severe long-term morbidities as discussed earlier. As such, there is increased awareness that nonspecific therapeutic options should be avoided in treating these children. Our ongoing efforts to
define the molecular mechanisms driving distinct PLGGs provide hope that there would soon be
better, less toxic targeted therapies for these clinically challenging childhood tumors.

Molecular Revolution: Utilizing concepts from PLGG gene fusions to inform
adult cancers
Adult LGGs have distinct molecular drivers (for example, IDH1/2 mutations, ATRX mutations
and 1p/19q co-deletions) and share negligible overlap with the mutation profile of pediatric
LGGs. In addition to vast differences in the molecular pathogenesis, adult and pediatric brain
tumors also differ in terms of predilection or tumor site in the brain, cellular microenvironment
and cell of origin (Baker, Ellison, & Gutmann, 2016). However, the genes implicated in PLGGs
are also mutated in several adult cancers, such as the MYB, BRAF, CRAF and QKI genes that
were under investigation in this study undergo various alterations in adult cancers. Our
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mechanistic findings have the potential to inform tumor mechanisms in adult cancers that involve
similar genetic mutations and have shared biology.
MYB is involved in frequent gene rearrangements, point mutations and deletion events in adult
cancers. Adenoid cystic carcinoma (ACC), a malignant cancer arising in salivary glands, is
associated with a hallmark MYB-NF1B fusion event (Ho et al., 2013). Interestingly, a recent study
has shown that similar to MYB-QKI, the gene rearrangement of MYB-NF1B also results in
translocation of enhancers close to the MYB promoter, resulting in activation of MYB promoter
(Y. Drier et al., 2016). Furthermore, MYB-NF1B was also found to bind and activate the MYB
promoter. These findings suggest that some of our mechanistic findings in MYB-QKI could be
universally applicable to other adult/pediatric MYB gene rearrangements and other gene fusions
that involve a proto-oncogene and tumor suppressor gene.
Our previous studies on therapeutic targeting of BRAF gene fusions have shown similar
resistance mechanisms to therapy in BRAF mutant melanomas (A. J. Sievert et al., 2013).
Paradoxical activation of the KIAA1549-BRAF fusion occurred due to vemurafenib therapy, and it
was later found that BRAFV600E mutant melanomas also exhibit paradoxical activation of
pathway as a resistance mechanism post initial response. These findings highlight that the basic
biological mechanisms retain some homogeneity across cancers of different age, cell of origin,
location, malignancy and prognosis. Our study on CRAF fusions also holds promise to inform
therapy for CRAF fusions identified in adult cancers such as prostrate cancer (ESRP1-RAF1,
AGGF1-RAF1), breast cancer (RAF1-DAZL, CMTM8-RAF1), thyroid cancer (AGGF1-RAF1) and
pancreatic cancer (HACL1-RAF1) (Fig. 3.1b). While deep sequencing studies have highlighted
the prevalence of CRAF fusions in several adult cancers, therapeutic targeting for majority of
these fusions remains unknown. Furthermore, a recent study found a rare CRAF point mutation
(R391W) as a driver mutation in melanoma where dimerization-dependent oncogenic
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mechanisms are also at play (Atefi et al., 2016). Therefore, our mechanistic findings on how
PLGG- associated CRAF fusions display distinct dimerization properties in response to inhibitors
could be extended to/tested for adult CRAF fusions and mutations, thereby guiding universal
personalized medicine approaches for all oncogenic CRAF fusions.

Conclusion
Overall, our study describes the unique mechanism of action of a new class of gene fusions in
pediatric low grade gliomas. QKI gene fusions, MYB-QKI and QKI-RAF1 are found to function
via involvement of both fusion partners thereby opening the field of fusion biology to new
possibilities. First, we found MYB-QKI to be a single, specific driver event in angiocentric
gliomas, which have not been associated with a molecular marker thus far. Second, we uncovered
the oncogenic mechanism of action of MYB-QKI to be a collaboration of gain-of-function of MYB
oncogene and partial loss of function of QKI tumor suppressor, along with involvement of
epigenetic events to drive aberrant MYB-QKI expression. Third, our study suggests that QKIRAF1 can activate the MAPK and PI3K signaling pathways but they are dependent on QKImediated dimerization, a finding that distinguishes them from other RAF fusions found in
PLGGs. Lastly, we report differential response to RAF targeted inhibitors in QKI-RAF1
expressing model systems due to stable dimerization induced by QKI fusion partner. Therefore,
we have shown how QKI gene fusions function to drive gliomagenesis in PLGGs, with broader
implications on biological mechanisms adopted by pan-cancer gene fusions and personalized
medicine approaches for PLGGs.
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Tables and Figures
Figure 4.1
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Figure 4.1. MYB-QKI drives oncogenesis in angiocentric gliomas via a tripartite
mechanism. MYB and QKI are located on chromosome 6q and intra-chromosomal deletion
leads to juxta-positioning of 5’ end of MYB with 3’ end of QKI, causing translocation of 3’UTR
enhancers. QKI-related enhancers can drive MYB promoter activation, leading to MYB-QKI
expression. MYB-QKI is oncogenic via additive effects of MYB gain of function and LOH of
QKI.
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Figure 4.2
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Figure 4.2. MAPK and PI3K oncogenic pathways driven by QKI-RAF1 and response to
targeted therapies. QKI-RAF1 exists as homodimers and heterodimers (with BRAF, CRAF
and QKI) that can activate the MAPK/ERK and PI3K/mTOR signaling pathways. While RAF
inhibitors (PLX4720 and PLX8394) cannot inhibit CRAF fusions, the novel RAF dimer inhibitor
LY3009120 could be a possible therapeutic option. Combinatorial targeting of downstream
MAPK and PI3K/mTOR pathways with MEK inhibitor trametinib and mTOR inhibitor
everolimus, respectively, has shown significant in vitro and in vivo efficacy.
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